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Abstract 
Green tea and hawthorn are two most popularly used Traditional Chinese Medicine 
(TCM). The major active ingredients of them are epicatechin (EC), epigallocatechin 
(EGC), epigallocatechin gallate (EGCG) and epicatechin gallate (ECG) for green tea 
and epicatechin (EC), isoquercitrin (IQ) and hyperoside (HP) for hawthorn. 
Although the beneficial effects of green tea catechins and hawthorn flavonoids are 
well documented, there is a lack of information concerning the extent of their in vivo 
uptake and the related oral absorption mechanisms. The present study aims to 
characterize the absorption mechanisms of the above components using Caco-2 cell 
monolayer model, one of the most well-known in vitro absorption models. 
Bi-directional transport studies were employed to examine the transport profiles of 
the studied compounds. Besides, transport in the presence of certain transporter 
inhibitors was also carried out to discover the possible transporters involved in the 
absorption process. Combination of HPLC/MS (mass spectrometry), HPLC/UV 
(ultraviolet detector) and HPLC/ECD (electrochemical detector) were employed to 
identify the metabolites generated during the transport of the studied compounds. In 
addition, transport profiles of the individual compounds of green tea catechins and 
hawthorn flavonoids, plant extracts of tea and hawthorn as well as the cocktail 
mixtures of green tea catechins and hawthorn flavonoids were investigated. 
Comparison of the metabolism and transport characteristics among the individual 
pure compounds, cocktail mixtures and plant extracts was also conducted to reveal 
the possible additive effect among different components and the contribution of 
II 
plant matrix in the absorption process of each active component of green tea and 
hawthorn. 
It was found that the studied green tea catechins and hawthorn flavonoids are 
absorbed via paracellular pathway. Efflux mediated by multidrug resistance 
associated protein-2 (MRP2) is involved in the transport of both green tea catechins 
and hawthorn flavonoids. In addition, structure related efflux was observed for the 
transport of the four green tea catechins. Methylated and sulfated metabolites are 
formed and actively transported by M R P 2 during the secretion transport of the 
studied compounds. Marginal additive effect among the active ingredients is 
observed only for the absorption of the three hawthorn flavonoids. Plant matrix is 
found to have no effect on the absorption of both green tea catechins and hawthorn 
flavonoids. When dosing with cocktail mixture, metabolic competition may take 
place during the secretion transport of green tea catechins, and transporter 
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Traditional Chinese medicines (TCM) are widely used in Asian countries, as 
they are considered to be effective and to have few side effects (Kam and Liew 
2002). In the western world, herbal drugs are also gaining increased popularity as 
complementary medicine (Fugh-Berman, 2000). Although T C M were developed by 
trial and error and largely based on empiric experience, studies on T C M would 
provide useful information for modem drug development. The combination of 
scientific method and traditional experience should be utilized to develop the T C M 
in the modem era. 
1.1 Flavonoids 
Flavonoids are a large group of natural phenoic compounds. More than 5,000 
specific compounds have been described. They are further classified as flavones, 
flavanols (catechins), isoflavonoes, flavonols, flavanones and anthocyanins (Yang et 
al., 2001) (Figure 1.1). Flavonoids are widely distributed in both edible plants and 
derived food. Previous studies indicated that the daily intake of flavonols and 
flavones is about 23 mg/day (Hertog et al., 1993a). The major dietary sources of 









Figure 1.1 Subgroups of flavonoids 
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Chapter One 
Flavonoids are reported to possess various beneficial effects, such as 
anticarcinogenie activity and prevention of low density lipoprotein (LDL) oxidation 
and coronary heart disease (Garewal, 1997; Yang et al., 2001). 
Although the health promoting effects of flavonoids have been well 
described, there is a lack of information concerning their oral absorption and 
bioavailability. Even though several studies have provided evidences for the uptake 
of specific flavonoids in rats and human, few researches have demonstrated the 
mechanisms of flavonoid absorption. In addition, most studies didn't distinguish the 
bioavailability of flavonoids as individual pure compound forms from that in the 
plant extracts or food form. Therefore, it is worth to study the effect of the co-
existing flavonoids as well as the matrix (i.e. the other co-occurring components 
besides the studied flavonoids) in herbal extract on the oral bioavailability of the 
active flavonoid components. 
For the current study, hawthorn and green tea, the two most widely used 
herbs rich in flavonoids, are chosen to investigate the intestinal absorption of their 
active flavonoid components. The proposed study aims to answer the following 
important questions such as 1): Which flavonoids in green tea and hawthorn are well 
absorbed. 2): Are the active transporters involved in the absorption of the studied 
flavonoids. 3): Will there be any difference in absorption when the active flavonoids 
in green tea and hawthorn are given as pure compound form versus in extract 
formulation? The present research results are expected to provide more information 
3 
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on the flavonoid absorption and promote the development of flavonoids as a more 
effective and safer medicine. 
1.2 Tea 
Tea {Camellia sinensis) is the most commonly consumed beverage in the 
world. There are three main commercial tea products: green tea, black tea, and 
oolong tea. They differ in the manufacturing processes. The green tea is subjected to 
the least amount of fermentation/oxidation in comparison to the other two products. 
Green tea contains flavonoids as active components, in which catechins (flavaii-3-ol) 
take up more than 10 % by weight in dry tealeaf (Takehiko and Mujo, 1997). 
1.2.1 Composition of green tea catechins (GTC) 
There are mainly six different catechins in green tea. Among them, in 
decreasing order of abundance are epigallocatechin gallate (EGCG), 
epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC), gallocatechin 
(G) and catechin (C). In general, G and C are usually trace or minor components. 
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1.2.2 Pharmacological activity 
The pharmacological effects of green tea are of great current interest. From 
in vitro, animal and human studies, G T C have been demonstrated to possess a 
variety of beneficial effects including anticarcinogenic, antioxidative, radical 
scavenge, cardiovascular, and antiviral effects. 
1.2.2.1 Anticarcinogenic activity 
E G C G and related polyphenols, including methylated E G C G , gallocatechin 
(GC), gallocatechin gallate (GCG), EGC, methylated G C G , catechin and EC, exhibit 
apoptosis-inducing activity for several cancer cell lines including human stomach 
and colon cancer cells (Isemura et al., 2000). The authors investigated the structure-
activity relationship and proposed that a pyrogallol-type structure is a must for 
cancer ap opto sis induction of catechins. In addition, the B ring in the molecule plays 
an important role in its activity. Studies in rodent cancer model have shown that 
green tea extract and E G C G inhibited carcinogenesis induced by a number of 
carcinogens, and the cancer chemoprevention was found in the target organs 
including colon, duodenum, esophagus, forestomach, large intestine, liver, lung, 
mammary glands and skin (Katiyar and Mukhtar, 1996). Epidemiological studies 
have linked the regular use of green tea to a reduced incidence of cancer (Benelli et 
al., 2002; Young et al., 2002). Other studies have also found that anticarcinogenic 
activity of G T C might be related to their antioxidative effect (Yang et al., 2001; 
Sang et al., 2002). 
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1.2.2.2 Antioxidative activity 
Human study suggested that the intake of G T C might increase antioxidative 
activity in the blood plasma (Young et al., 2002). G T C supplement has been 
revealed to modulate lipid peroxidation damage in lead-exposed HepG2 cells (Chen 
et al., 2002). In vitro studies showed that catechins, particularly E G C G , help prevent 
oxidation of plasma L D L (Miyazawa, 2000; Leung et al., 2001). The anti-LDL 
oxidative potencies of G T C in decreasing order are E G C G « E C G > E C > E G C (Osada 
et al., 2001). Based on the study of the structure related antioxidative activity, the 
presence of the gallate group at the 3-OH position plays an important role in the 
protection against protein oxidation (Nakagawa et al., 2002). In addition, hydroxyl 
group at the 5' position in the B ring may also contribute to the antioxidative 
activity. 
1.2.2.3 Radical scavenge 
G T C were found to exhibit radical scavenging activity (Guo et al, 1999). 
The structure activity relationship study for G T C suggested that the presence of 
3',4',5'-trihydroxyl groups on the B-ring of catechins might enhance the radical 
scavenging efficiency in comparison to those with 3’,4’-dihydroxyl groups, and the 
conjugation of a gallate group at the 3 position of the C-ring exerted a synergistic 
impact on radical scavenging activity (Unno et al., 2002). 
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1.2.2.4 Cardiovascular activity 
Recent epidemiological studies suggested an inverse relationship between tea 
consumption and cardiovascular disease risk (Duffy et al., 2001; Keli et al., 1996; 
Geleijnse et al., 1999; Sesso et al., 1999). Similar conclusion was also made after 
assessing the flavonoid intake in 805 men (Hertog et al., 1993b). In the studies from 
sixteen cohorts of seven countries on the contribution of flavonoid intake (mainly 
from tea, apples, onions, and red wine) on coronary heart disease (Hertog et al., 
1995), the finding was also consistent with the previous suggestion. 
1.2.3 Pharmacokinetics of GTC 
Since the physiological effects of the drugs are proportionally related to their 
concentrations in the blood, studies on pharmacokinetics are crucial for 
extrapolation of in vitro pharmacological effects to in vivo situation. 
As tealeaves are commonly utilized in tea beverages, most in vivo 
pharmacokinetics studies focused on the characterization of the pharmacokinetic 
profile of the major four G T C after oral administration of tea extract or pure 
catechins. Table 1.1 summarizes the major pharmacokinetic parameters of the GTC 
obtained from previous human and animal studies. 
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Table 1.1 Summary of major pharmacokinetic parameters of tea catechins 
after oral administration  
Substance Species Dose C^^ T^ax Un Analytes Ref. 
iSire human 200 mg T ^ 127 mm 157 min Total blood Chow et 
EGCG (ng/ml) concentration al., 2001 
400 mg 111.8 108 min 162 mm (including 
(ng/ml) conjugated 
600 mg 169.1 180 min 183 min and 
(ng/ml) unconjugated 
800 mg 438.5 240.6 min 114 mm forms) 
(ng/ml)  
Tea human EGCG: 165.7 216 mm 118 mm Total blood Chow et 
extract 600 mg (ng/ml) concentration al., 1997 
EGC: �1 6 0 � 2 5 0 min 
111 mg (ng/ml) 
EC: � 1 5 0 -240 mm 
93 mg (ng/ml) 
Black tea human EGC: 145 nmol/1 Total blood Warden 
(multiple 15.48 mg concentration et al., 
doses) EGCG: 21 nmol/1 2001 
36.54 mg 
EC: 174 nmol/1 
16.74 mg 
ECG: 50.6 nmol/1 
31.41 mg  
DGT human EGCG: 119 ng/ml L ^ 5.5 h Total blood Yang et 
powder 109 mg concentration al., 1998 
EGC: 148 ng/ml 1.4 h 2.7 h 
102 mg 
EC: 55 ng/ml 1.4 h 3.7 h 
37.5 mg 
R^^e mt EGCG: 19.8 ng/ml 85 mm 135 min Total blood Chen et 
EGCG 22.5 mg concentration al, 1997 
DGT mt EGCG: 16.3 ng/ml 74 mm 212 min 
extract 4.38 mg 
EGC: 1432 ng/ml 64 min 45 mm 
4.08 mg 
EC: 685 ng/ml 54.6 min 41 min 
1.62 mg 
DGT mt ^ 15.4 昭/ml 120 min 45 mm Blood Zhu et 
extract 62.5 mg concentration al., 2000 
EGCG: 112 Lig/ml 115 mm 191 min of ‘ � 625 m unconjugated 
ECG: 14.8 }xg/ml 125 mm 362 mm 
162.5 mg  




G T C are absorbed from gastrointestinal tract. Direct evidence on the 
absorption of EGC, EC, E G C G and E C G was provided by detecting the four 
catechins in the portal vein of rats after oral administration (Okushio et al., 1996). 
One of the studies showed that after intragastric administration of decaffeinated 
green tea extract (200 mg/kg), 13.7% of E G C and 31.2% of EC appeared in plasma, 
but only 0.1% of E G C G was bioavailable (Chen et al., 1997). Another study in rats 
after oral administration of decaffeinated green tea extract indicated that the 
bioavailability of EC, E G C G and E C G was 39%, 14% and 6%, respectively (Zhu et 
al., 2000). The animal experiment data indicated that the oral bioavailability of the 
four green catechins was relatively low and the gallated catechins (such as E G C G 
and ECG) seemed to be even lower than the nongallated catechins (such as EC and 
EGC). Human studies on the pharmacokinetics of tea catechins have also been 
reported. Chow et al. determined the oral absorption extent of G T C after single dose 
of oral administration of E G C G and decaffeinated G T C mixture (Chow et al., 2001). 
Since the oral bioavailability of G T C is low, the authors suggested that a significant 
fraction of the orally administrated tea catechins should be eliminated 
presytemically. Such findings also agreed with a previous human study with black 
tea, which indicated the gallated catechins possess even lower bioavailability in 
comparison to nongallated catechins (Warden et al., 2001). 
Although the effect of different dosing forms (administrating with extract or 
single pure compound) on the extent of absorption has been investigated, the results 
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were not complete and quite controversial. Animal study on rats showed that oral 
administration with green tea extract produced higher Cmax and A U C of E G C G than 
that after the oral administration of the same amount of single pure E G C G (Chen et 
al., 1997). The authors speculated that the green tea extract delivered E G C G into the 
blood more effectively than when E G C G was given in pure compound. However, a 
human study demonstrated that pure E G C G and decaffeinated G T C extract 
containing the same amount of E G C G resulted in similar plasma concentrations of 
E G C G (Chow et al, 2001). 
1.2.3.2 Distribution 
E G C G is more widely distributed into peripheral compartment than E G C and 
EC (Chow et al., 2001). Another experiment also verified this finding with an oral 
administration of [^H] E G C G to mouse. It was found that there was a wide 
distribution of [^H] E G C G in digestive tract, liver, lung, pancreas, mammary gland, 
skin, brain, kidney, uterus, ovary and testes (Suganuma et al., 1998). 
1.2.3.3 Elimination 
Elimination of the nongallated catechins (EGC and EC) was found to be 
faster than gallated catechins in rats (Chen et al., 1997). This was reflected by 
relatively smaller elimination half lives for E G C and EC. The same study also found 
that E G C G was excreted mainly through the bile, while E G C and EC were excreted 
through both urine and bile. By comparing the plasma concentration time profile of 
tea catechins following intravenous and intraportal administration of EC, E G C and 
EGCG, these three G T C were found to undergo minimal hepatic elimination with 
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almost identical pharmacokinetics characteristics after the two different 
administration routes (Cai et al, 2002). These results suggested that hepatic 
elimination might not be the major cause for the low oral bioavailability of GTC. 
1.2.3.4 Metabolism 
A number of studies reported that tea catechins were metabolized extensively 
following oral administration of GTC. The major metabolites in biological fluids 
(the plasma, bile and urine) of the rat after oral administration of EC were 
epicatechin-5-0-|3-glucuronide and 3'-0-methyl-epicatechin-5-0-P-glucuronide. 
The metabolite concentrations were much higher than the parent compound (Harada 
et al., 1999; Okushio et al., 1999a). Human studies also showed a much higher 
concentration of the glucuronide or sulfate conjugates of EGC, EC and E G C G in 
plasma and urine than that of their parent compounds following oral administration 
of green tea extract (Lee et al., 1995). Another human study discovered that 4,-0-
methyl-EGC was the major metabolite in the blood, with a maximum blood 
concentration 4 to 6 fold-higher than that of EGC. The accumulative amount of 4'-
0-methyl-EGC in urine in 24 hours was about 3 times higher than that of E G C 
(Meng et al, 2001). 
1.2.3.4.1 Metabolism in the small intestine 
Rat isolated jejunum perfusion experiment with EC demonstrated that the 
glucuronidated metabolites (-45%), 3'-0-methyl-EC and 4'-0-methyl-EC (10%), 
and 0-methyl-glucuronidated metabolites (〜20o/o) were formed during its transfer 
across the enterocytes to the serosal side of the small intestine (Kuhnle et al., 2000). 
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Metabolism study by human intestinal microsome demonstrated that EC was 
efficiently sulfated but not glucuronidated (Vaidyanathan and Walle, 2002). 
Comparison of the types of the metabolites formed in rat and human subjects 
indicated that there was species difference in both glucuronidation and sulfation of 
EC. 
1.2.3.4.2 Metabolism in the liver 
Incubation of EGC, E C G and E G C G with rat liver homogenates resulted in 
methylated catechins. Analysis with mass spectrometry (MS) and nuclear magnetic 
resonance (NMR) showed that the metabolites were 4‘-0-methyl-EGC, 4"-0-
methyl-ECG and 4”-0-methyl-EGCG, respectively (Okushio et al., 1999b). The 
species difference (between rats and humans) also existed with the metabolism of 
EC in the liver (Vaidyanathan and Walle, 2002). It was found that EC was 
preferentially glucuronidated by rat liver microsome, while the sulfation was the 
major pathway in EC metabolism in the human liver microsome with no 
glucuronidation occurring. 
1.2.3.5 Summary of the pharmacokinetics of GTC 
A number of human and animal studies consistently demonstrated that the 
bioavailability of the four major G T C was low and the extent of oral absorption of 
non-gallated is lower than that of the gallated catechins. Intensive pre-systemic 
elimination of the G T C was proposed to be the major cause to their low 
bioavailabilities. Hepatic elimination was believed to have minimal contribution to 
the low bioavailability of GTC. Therefore, studies on intestinal absorption could 
13 
Chapter One 
provide valuable information to explain the low bioavailability of GTC. In addition, 
methylation, glucuronidation and sulfation are believed to be the major metabolic 
pathways of GTC. 
1.3 Hawthorn 
Hawthorn {Crataegus) has been used as T C M for a long history (Gao and 
Feng, 1994). In China, hawthorn fruits are used to improve digestion and relieve 
food stasis (Ding et al., 1990; Chen et al., 1995). In Europe, fruits, leaves and 
flowers of hawthorn have been used for astringent, diuretic, and cardiovascular 
condition (Leung et al., 1996; Cupp et al., 2000). 
1.3.1 Composition of hawthorn 
Compounds isolated and identified in hawthorn include sterols, triterpene 
acids, flavonoids, oligomeric proanthocynanidins, organic acids and cardioactive 
amines etc. (Schulz et al., 2001; Chang et al., 2002a). The pharmacological effects 
are believed to be due to the hawthorn flavonoids (HF), which mainly composed of 
hyperoside, quercetin, quercitrin, isoquercitrin, rutin, vitexin, isovitexin and 
epicatechin (Pietta et al, 1986; Rehwald et al., 1994; Chang et al., 2001). EC, 
isoquercitrin (IQ), and hyperoside (HP) (Figure 1.3) are the major flavonoids in 
hawthorn fruit extract with strong antioxidative activities (Zhang et al., 2001). 
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Figure 1.3 Structures of hawthorn flavonoids 
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1.3.2 Pharmacological activity 
Pharmacological studies of hawthorn indicated that it possesses quite a 
number of beneficial effects, including inotonic, antiarrhythmic, antihypertensive, 
hypolipidemic and antioxidative activities. 
1.3.2.1 Inotonic activity 
Preparations made from hawthorn leaves, flowers, and berries are used for its 
cardiotonic activity in Europe (Awang and Fugh-Berman, 2002). An animal study 
with isolated cardiac myocytes from rats revealed that the hawthorn extract had a 
positive inotonic effect accompanied with an increase of energy turnover and 
prolonged apparent refractory period (Popping et al., 1995). Isolated guinea pig 
hearts were also used to evaluate the inotonic effect of HF and the results showed 
that flavonoid 0-glycosides and C-glycosides exerted positive inotropic effects. The 
mechanism of cardiac action of flavonoids was proposed to be due to the inhibition 




1.3.2.2 Antiarrhythmic activity 
Hawthorn extract has been shown to possess actions against arrhythmia 
(Garjani, 2000). It was found that hawthorn extract was able to block both the 
delayed and inward rectifier K+ current (Muller et al., 1999) and increase the action 
potential duration (Muller et al., 1996). 
1.3.2.3 Hypolipidemic activity 
Hawthorn has been shown to possess beneficial effect on the reduction of 
serum lipids. Rabbits fed with hawthorn fruit powder for 12 weeks were found to 
have a significant decrease in their total cholesterol and triglyceride levels in the 
serum with reductions of 23.4 and 22.2%, respectively in comparison with the 
control. The authors also observed that the activities of hepatic 3-hydroxy-3-
methylglutaryl CoA reductase or cholesterol 7a-hydroxylase were not been affected, 
whereas the activity of intestinal acyl CoA cholesterol acyltransferase (ACAT) was 
decreased. Therefore, the involvement of inhibition of cholesterol absorption 
mediated by down-regulation of intestinal A C A T enzyme activity was proposed as 
the mechanism by which dietary hawthorn fruit exerts hypolipidemic activity 
(Zhang et al., 2002). In addition, studies in rats and mice confirmed the finding of 
decreased plasma lipid levels after intake of hawthorn extract (Shanthi et al., 1994). 
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1.3.2.4 Antihypertensive activity 
Hawthorn extract has also been demonstrated to possess antihypertensive 
activity. Injection of hawthorn extract to rats caused a significant reduction in the 
blood pressure (Garjani et al., 2000). The extract prepared from hawthorn was 
examined with rat isolated mesenteric arteries and significant vasorelaxation induced 
by hawthorn extract was found (Chen et al., 1998a). The mechanism probably 
involved nitric oxide. The procyanidins in the hawthorn extract were believed to be 
responsible for the endothelium-dependent nitric oxide-mediated relaxation in the 
isolated rat aorta (Kima et al., 2000). 
1.3.2.5 Antioxidative activity 
Flavonoids from hawthorn fruits have been shown to protect human LDL 
/-J 1 • 
from Cu mediated L D L oxidation and prevent the peroxy free radical induced 
oxidation of a-tocopherol in human L D L (Zhang et al., 2001). Investigation 
indicated that the flavonoids from hawthorn leaves as well as proanthocyanidins and 
catechins from hawthorn flowers and fruits are the major sources of antioxidants 
(Bahorun et al., 1994). 
1.3.3 Pharmacokinetics of HF 
Although the beneficial effects of hawthorn are well accepted, the 
pharmacokinetic profiles of hawthorn extract as well as the major HF were only 
studied by our research group recently (Chang, 2002b). So far, in vivo 
pharmacokinetic study of HP has barely been reported. The in vivo data of EC were 
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mainly generated from the studies after oral administration of green tea instead of 
hawthorn (Chen et al., 1997; Chow et al., 2001). Although a number of studies on 
the extent of oral absorption of IQ were reported, the results were contradictory 
among different laboratories. 
1.3.3.1 Absorption 
EC were generally studied as one of the components of green tea and its 
pharmacokinetic data were mostly generated after co-administration with other 
GTC. The oral bioavailability of EC after oral administration of green tea extract 
was about 30% (Chen et al., 1997; Zhu et al., 2000). 
Recently, a study from our research group indicated that there was no HP 
(quercetin-3-galactoside) detected in rat plasma after oral administration of either 
pure HP or hawthorn extract containing same amount of HP (Chang et al., 2002c). 
A number of studies on the oral absorption of IQ (quercetin-3-glucoside) 
have been conducted without a consistent conclusion. It is generally believed that 
the flavonoid glycosides have to be hydrolyzed to their aglycone before being 
absorbed (Manach et al., 1997; Walle et al., 2000), However, recent oral absorption 
study of quercetin glycoside in ileostomy patients indicated that the extent of oral 
absorption of quercetin glucosides from onions was even better than quercetin, the 
aglycone and the sugar moiety was a major determinant of oral bioavailability of 
quercetin glycosides (Hollman et al., 1995; Hollman et al., 1999). It was suggested 
that the superior oral absorption of quercetin glucoside might be due to the active 
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transport by sodium glucose co-transporter (SGLTl) (Hollman et al, 1995). 
However, in the above study, the plasma samples were all subjected to hydrolysis 
and the concentrations of the aglycone in the plasma were examined. Both flavonoid 
glucosides and the glucuronidated conjugate of the aglycone could be hydrolyzed by 
the P-glucuronidase, which was used for the hydrolysis treatment. Therefore, the 
study could not confirm whether detected concentration of aglycone is from 
quercetin glucoside absorbed as its intact form or from the quercetin glucuronide 
formed during the absorption of its aglycone. 
Several absorption studies were subsequently carried out trying to explain 
the absorption mechanism of IQ. One study on transport of IQ was performed with 
Ussing chamber (Wolffram et al., 2002). The results showed that IQ loaded to the 
mucosal chamber disappeared significantly and the disappearance of IQ was reduced 
in the presence of phloridzin, a SGLTl inhibitor. Thus, it was concluded that 
SGLTl might be involved in the uptake of IQ in the small intestinal. However, the 
disappearance of IQ did not necessarily reflect the amount of the compound 
transported. The active transport of IQ via SGLTl still needs to be confirmed. 
Other studies with isolated intestinal mucosa found that IQ competitively 
inhibited the active absorption of methyl-a-D-glucopyranoside (MDG), a non-
metabolisable glucose analogue, while quercetin and rutin did not show similar 
inhibitory effect (Ader et al., 2001). As the absorption of M D G is mediated by 
SGLTl, the author concluded that IQ might be absorbed by SGLTl as well. Once 
again, the study could not give direct evidence on the absorption of IQ even though 
IQ may competitively inhibit the transport of M D G . 
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Another confounding factor is the hydrolysis of IQ in intestine before its 
absorption, which was demonstrated in rat intestinal perfusion model (Sesink et al., 
2003). However, the study could not elucidate how much contribution of hydrolysis 
accounted for the entire IQ absorption. Furthermore, the assay used in that study for 
determination of the plasma concentration was based on hydrolyzing the plasma 
samples followed by quantification of the aglycone concentration. Therefore, the 
studies still could not differentiate whether the existing form of IQ in the blood 
stream is the parent compound of IQ or the glucuronide of quercetin. 
Recently, the extent of oral absorption of HF in rats was studied by our 
group (Chang, 2002b). The study indicated that only EC and IQ in the hawthorn 
extract were bioavailable orally, while HP was not. In addition, the study also 
compared oral bioavailability of pure active components, EC and IQ, with plant 
extract containing equivalent amount of EC and IQ. The result showed that similar 
bioavailability of EC and IQ was observed after oral administration of either pure 
active components or plant extract. 
1.3.3.2 Distribution and elimination 
Our research group has investigated the apparent volume of distribution ( V d ) , 
elimination half-life (ti/2) and clearance (CL) of EC, HP and IQ after i.v. 
administration of each pure compound individually and in hawthorn extract 
formulation (Chang et al., 2002d). EC was found to exhibit smallest elimination rate, 
largest Vd, smallest CL and longest tyi among the three HF. The Vd, ti/2 and CL are 
similar for IQ and HP. Compared with the individual pure forms, i.v. administration 
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of hawthorn extract resulted in a significantly reduced Vd and increased im of EC, 
HP and IQ. These results indicated that the competition with other co-existing 
components for the plasma protein and binding site of the tissue could be 
responsible for changed Vd and tm in extract form. 
1.3.3.3 Summary of pharmacokinetics of HF 
Hawthorn mainly contains quercetin glycosides, HP and IQ, in addition to 
EC. EC and IQ were orally bioavailable, while HP was not. Whether IQ is actively 
transported by SGLTl or other transporters is uncertain and needs to be verified. 
Competition among the three HF might lead to the change of their pharmacokinetics 
parameters ( V d , im and CL) after the i.v. administration of the hawthorn extract. In 
addition, no difference was observed on the extent of bioavailability of active 
components after oral administration of either extract or equivalent amount of pure 
HF. So far, the absorption mechanisms of the three HF have not been clearly defined 
yet and need further investigation. It is worth to investigate the potential effect of the 
co-existing HF and matrix from the extract on the extent of absorption of each active 
HF. 
1.4 Mechanisms of intestinal absorption 
In general, there are three major pathways for the intestinal absorption of 
drugs including passive transcellular transport, paracellular transport and carrier-
mediated transport (Shargel and Yu, 1999). 
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1.4.1 Passive transcellular transport 
Most of the well-absorbed drugs are predominantly transported by this 
pathway (Stenberg et al., 2002), which favors lipophilic and unionized molecules. 
The drugs transported by this pathway follow Pick's law of diffusion. According to 
Pick's law, the rate of diffusion is positively proportional to lipid-water partition 
coefficient of each drug in the biological membrane (Shargel and Yu, 1999). This 
indicated that reasonable lipophilicity is essential for the efficient absorption of a 
drug. Hydrophilic as well as ionized molecules would be restricted to transverse 
across the intestinal epithelium. 
1.4.2 Paracellular transport 
Hydrophilic solutes with inferior transcellular transport property may cross 
the intestinal epithelium via water-filled pore between the cells i.e. paracellular 
pathway. Molecular size is an important factor for drugs transported through this 
route. In general, drugs with molecular weight above 500 would exhibit poor 
intestinal absorption through the paracellular pathway (Shargel and Yu, 1999). The 
intercellular space has been reported to account for only 0.1-0.01% of the surface 
area of the intestine (Barthe et al., 1999), suggesting that contribution of paracelluar 
transport is limited. 
1.4.3 Carrier-mediated transport 
This pathway mainly involves the absorption of essential nutrients for the 
body such as amino acid, glucose, bile acid etc (Shargel and Yu, 1999). Drugs with 
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similar structures as these nutrients can also be transported by the same pathway. 
For example, methyldopa and gabapentin are actively absorbed through amino acid 
transporter (Amidon et al., 1986; Stewart et al., 1993). Cephradine and bestatin are 
transported via oligopetide transporter (Okano et al., 1986; Takano et al, 1994). 
Phosphate transporter is involved in the active transport of fostomysin (Shargel and 
Yu, 1999). Glucose transporter mediates absorption of p-nitrophenyl-P-D-
glucopyranoside (Tsuji and Tamai, 1996). Because of high efficiency of these active 
transporters, chemical structure modification to adapt to the relevant absorption 
transporter is one of the potential strategies to improve the absorption of the poorly 
absorbed drugs. 
1.5 ABC transporters 
In addition to the transporters mentioned above, a class of transporters 
named the ATP binding cassette (ABC) transporters is also involved in the intestinal 
absorption of some drugs (Suzuki and Sugiyama, 2000). 
The ATP binding cassette superfamily is one of the largest and most 
widespread protein superfamilies. Its members are responsible for the active 
transport of a wide variety of compounds across the biological membranes to 
prevent the accumulation of these compounds in the cells (Klein et al., 1999). As 
A B C transporters prefer to transport their substrates out of the cells, they were also 
called ‘‘efflux transporters". 
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A surface glycoprotein modulating drug permeability in Chinese hamster 
ovary cell mutants was discovered in 1976 and was named P-glycoprotein with a 
molecular weight of 170Kda (Juliano et al., 1976). In 1986, the multidrug resistance 
(MDR) gene encoding P-gp was cloned (Chen et al., 1986; Gros, 1986). In 1992, 
Cole and colleagues cloned a new gene encoding for one member of another 
subfamily of A B C transporters, the multidrug resistance-associated protein-1, M R P l 
(Cole et al., 1992). Later on, the other 5 members (MRP2 to MRP6) of M R P family 
were revealed (Litman et al., 2001). Recently, another member of A B C transporters 
designated as M X R (mitoxantone resistance) protein was identified (Allikmets et al., 
1998; Miyake et al, 1999). 
1.5.1 Cellular location and tissue distribution 
P-gp is present with high levels at tissues including the luminal membranes 
of renal proximal tubules, the biliary canalicular membrane of hepatocytes, the 
apical surface of mucosal cells in the small and large intestine, and capillary 
endothelial cells of blood brain barrier (Cordon-Cardo et al., 1989; Thiebaut et al., 
1987). 
The six members of M R P family have various locations in polarized cells 
and diversified tissue distribution. M R P l distributes ubiquitously in the body and is 
located on the basolateral side of the polarized cells (Ever et al., 1996). MRP2, the 
second member of the M R P family, shares a close similarity to M R P l with respect 
to structure and substrate selectivity, but bears different localizations in cells and 
tissue (Brost et al. 2000; Biichler et al., 1996). M R P 2 is mainly expressed in apical 
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membranes of liver, kidney and gut (Paulusma et al., 1996). MRP3, bearing the 
highest degree of structure similarity to MRPl, is located at the basolateral side of 
liver, kidney and gut (Borst et al., 2000). Relatively fewer data on the M R P 4 to 
M R P 6 are reported and their cellular location is not well elucidated. 
In summary, P-gp, M R P 1，MRP2 and M R P 3 are the most well studied A B C 
transporters and their locations in cells are summarized in Figure 1.4. 
r O r O ] ~ T ~ 1 
^ MRPl MRP3 
P-gp MRP2 
I ^ ~ H p - H p ^ 
Basal side T • 
Figure 1.4 Cellular locations of major A B C transporters 
1.5.2 Substrates and inhibitors of ABC transporters 
P-gp has a wide variety of substrates. Over the past ten years, the substrate 
spectrum extended from initially reported vinca alkaloid and anthracyclines to an 
array of structurally unrelated chemicals, such as anticancer drugs (such as 
camptothecin derivatives, epipodophyllotoxins), anti HIV drugs (like ritonavir, 
saquinavir), and fluorophores (calcein-AM, fluo-3AM, rhodamine 123) (Litman et 
al., 2001). It is widely believed that the efflux transporters such as P-gp and MRPs 
are responsible for the chemotherapy resistance. 
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Inhibitors of A B C transporters can reverse drug efflux and increase the drug 
accumulation in the resistant cancer cells. Calcium channel blocker, verapamil, and 
calmodulin antagonist, trifluoperazine, can selectively reverse P-gp mediated 
resistance (Ford, 1996). In early clinical trials, verapamil has been combined with 
standard chemotherapy in refractory lymphoma and myeloma and encouraging 
results have been obtained (Sonneveld, 1996). Cyclosporin A is another P-gp 
inhibitor that has demonstrated the improved therapeutic efficacy on unresponsive 
patients (Sonneveld et al., 1992). PSC-833, a cyclosporin derivative, belongs to a 
new generation of P-gp inhibitor developed by Sandoz and has been shown to have a 
10-20 fold higher potency than cyclosporin A without any immunosuppressive 
effect (Gaveriaux et al., 1991). 
Venn diagram summarizes the substrates of P-gp, M R P and M X R (Figure 
1.5). As MRPs and P-gp both belong to the A B C superfamily, some compounds are 
substrates of both. Although substrate selectivity seems to be similar between P-gp 
and MRPs in the early studies, notable different substrate spectrum exists. In 
general, M R P prefers substrates such as organic anions and Phase II metabolites e.g. 
glutathione (GSH), glucuronidated and sulfated conjugates, whereas P-gp has a 
higher affinity for organic cations (Brost et al., 2000; Miiller et al., 1994). It was 
proposed that the extracytosolic NH2-teraiinus of M R P might contribute to its 
preference to interacting with the organic anions (Tusnady et al., 1997; Keppler et 
al., 1998). 
The substrate selectivity of the six members of M R P family is very close. 
M R P l transports glutathione conjugates such as Leukotriene C4 (LTC4) and 2,4-
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dinitrophenyl-S-glutathione (DNP-SG) (Jedlitschky et al., 1994), glucuronide 
conjugates (Jedlitschky et al., 1996) such as estradiol 17-p-D-glucuronide (E2l7pG), 
sulfate conjugates such as dianionic bile salts (Loe et al, 1996). MRP2, an isoform 
of M R P l with an identity of 49% amino acid sequence, bears similar substrate 
selectivity as M R P l (Biichler et al., 1996). Among members of M R P family, M R P 3 
shares the most similarity to M R P l with 58% of identical amino acid (Kool et al., 
1998). However, unlike M R P l and MRP2, M R P 3 prefers to transport glucuronide 
conjugates instead of G S H conjugates (Hirohashi et al., 1999). M R P 4 and M R P 5 are 
transporters of nucleotide analogue (Schuetz et al., 1999; Wijnholds et al., 2000). 
The substrate specificity of M R P 6 remains to be determined. 
In order to reverse the efflux mediated by MRPs, M R P inhibitors could be 
used. One of the characteristics of efflux mediated by MRPs is the participation of 
glutathione (GSH). Some M R P substrates can be conjugated to G S H then 
transported by MRPs. Others, which do not conjugate with glutathione, would be 
co-transported with G S H by MRPs (Borst et al., 2000). Thereby, the intracellular 
G S H levels could regulate drugs transported by MRPs. According to this principle, 
G S H synthesis inhibitor, such as buthionine sulfoximine (BSO), is used as one of 
the MRPs inhibitors to increase the cellular concentration of M R P substrates in cells 
(Twentyman et al., 1997). In addition, M K 571, a quinoline-based Leukotriene D4 
(LTD4) analog, can modulate M R P mediated drug resistance and has been used 
commonly for the inhibition of M R P (Gekeler et al, 1995). 
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Figure 1.5 Venn diagram indicating the overlapping substrate specificity of M D R , M R P 
and M X R . (Litiman et al., 2001) 
M D R : Multidrug resistance protein (P-gp). 
MRP: Multidrug resistance associated protein. 
M X T : Mitoxantrone resistance protein 
BIS, bisantrene; CA, calcein; CA-AM, calcein-AM ester; COL, colchicine; 
D N R , daunombincin; D O X , doxorubicin; EPI, epimbicin; LYS, Lyso 
Tracker; M C B , monochlorobimane; M X , mitoxantrone; PRA, prazosin; 





































































































































































































































































































































































































































































1.6 Oral absorption models 
Although in vivo oral absorption studies are most reflective of macroscopic 
biopharmaceutical processes following drug administration, it is difficult to 
determine the mechanism at the cellular or molecular level. Thus, in vitro models 
should be employed in order to elucidate absorption mechanism at the molecular 
level. 
Oral absorption is subject to several factors, such as chemical and enzymatic 
stability of the drug in GI tract, degradation by bacteria, solubility and dissolution of 
the drug in the gastrointestinal fluid and permeability to the epithelium of GI tract 
(Stenberg et al., 2002). Even though in vivo studies could give the overall picture on 
entire process of the drug absorption, they could not identify the contribution of each 
factor to the oral absorption. Certain in vitro absorption models are capable of 
evaluating the permeability of drugs, which is regarded as one of the most important 
properties in determining the oral bioavailability (Stenberg et al., 2002). 
At present, the most widely used in vitro absorption models consist of 
Ussing chamber, in situ intestinal perfusion model and cultured cell model. 
1.6.1 Ussing chamber 
Ussing chamber is composed of two transport buffer containing chambers 
separated by an isolated intestinal mucosa (Figure 1.6). The permeability of drugs 
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could be evaluated by examining the rates of transport across the mucosa (Barthe et 
al., 1999). Limitations of this model are documented. Yamashita et al. (1997) 
compared the permeability of several drugs with different lipophilicities obtained 
from Ussing chamber model and in vivo situation. They found no close relationship 
between in vitro and in vivo drug permeability results. For example, propranolol, a 
drug with perfect intestinal epithelium permeability in vivo, hardly penetrated 
through the isolated mucosa in Ussing chambers. In in vivo situations, drugs just 
need to cross the intestinal epithelium, which is a monolayer, before entering into 
the blood circulation. In contrast, for isolated mucosa, permeation required the 
diffusion of drug from mucosal to serosal side of the mucosa. In this process, extra 
absorption barrier besides the epithelial monolayer existed. Lipophilic drugs, such as 
propranolol, need to pass the extra barrier and will result in substantially reduced 
permeability (Yamashita et al, 1997). Another concern of the Ussing chamber is the 
viability of the isolated tissue. Histological study demonstrated that 20 min of 
incubation in the transport medium can cause a severe damage to the intestinal 
villous epithelium (Plumb et al., 1987). 
0 0 Q ^ Transport buffer 
一 L— V 
k 
Cg c  
‘ 5% CO2/O2 
〔 ）（ 
^ ^ ^ J J ^ ^ Serosa 
chamber 
\ Intestinal tissue 
^ Mucosa chamber 
Figure 1.6 Illustration of Ussing chamber 
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Additionally, the samples from the Ussing chamber with a relative large volume 
may raise a potential problem on the detection sensitivity for the tested compounds 
(Barthe et al., 1999). 
1.6.2 In situ intestinal perfusion model 
In situ model mimics the in vivo situation. The model consists of a segment 
of the intestine from an anesthetized animal, which is connected to a single 
mesenteric vein. The vein is cannulated and perfused with the studied drug solution. 
The blood from the mesenteric vein is collected and the drug concentration in the 
blood is measured to determine the rate of absorption of the studied drug (Figure 
1.7). The major disadvantage of this model is that it requires complicated surgical 
technique and may not provide the information on absorption mechanism at the 
cellular or molecular level (Barthe et al., 1999). 
1 1 
. ] — 2 0 cc. plastic syringe 
• ^ — Hole at lOcc. mark 
效 fe_ 3-Way Stopcock 
P Tygon tubing 
Y WJ L-shaped glass cannula 
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superior Mesenteric ？ 丨 c ) Vein 
《么广 / 1 1 k \ Infusion Pump 
r ^ ,, / n ^ ^ for Donor Blood 
Blood Pressure Teflon Cathete — T o p ^ � 
Monitor (24 G x 1.6 cm) Vacutainer I V U 
Figure 1—In situ rat intestinal preparation. 
Figure 1.7 In situ intestinal perfusion model 
(Blanchard et al.，1990) 
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1.6.3 Cell culture model 
In recent decade, Caco-2 cell model has become popular to study the 
absorption of drugs (Figure 1.8). This model has been well correlated with in vivo 
studies, especially for those drugs transported via passive diffusion (Artursson et al., 
1997). 
The Caco-2 cell is an immortal cell line derived from human colon 
carcinoma and can be developed as a polarized monolayer on porous support 
(Barthe et al., 1999). This cell line resembles small intestine enterocytes 
morphologically, exhibiting well-defined brush border on the apical side. In 
addition, expression of Phase I and Phase II metabolizing enzymes has been 
verified. Analysis with Genechip to compare the expression of Phase I metabolic 
enzymes (cytochrome P-450) and Phase II metabolic enzymes 
(glucuronosyltransferase, glutathione S-transferase, sulfotransferase, N-
acetyltransferase and acyltransferase) between human duodenum and Caco-2 cell 
have been conducted (Sun et al., 2002). The existence of these enzymes in the 16-
day cultured Caco-2 cells were verified and but the levels of the expression of Phase 
I and Phase II enzymes in the Caco-2 cells was found to be lower than those in the 
human duodenum. The same study also found that several active absorption 
transporters that existed in intestine epithelium, such as transporter for glucose, 
amino acids, dipeptide, bile acid etc, were present in the Caco-2 cells. Several 
cohorts demonstrated the presence of P-glycoprotein and M R P 2 in Caco-2 cells 
(Hunter et al., 1993; Gutman et al., 1999). Thus the model can be used to determine 
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Figure 1.8 Scheme of Caco-2 cell model 
There are several advantages of utilizing Caco-2 monolayer model to study 
the absorption mechanism. First, the polarity of the cell differentiation makes it 
possible to study the implication of active transport by characterizing the bi-
directional rate of transport (from apical to basalateral side and from basalateral to 
apical side). Second, origin from human source diminishes the species-related 
differences, which especially benefits the prediction on the type of metabolites in 
human. Third, the experimental condition such as pH of transport buffer and drug 
concentration can be easily controlled in Caco-2 cell model. 
Nevertheless, attempts to employ Caco-2 cell model for prediction of the 
actively absorbed drugs achieved less success than that for the passively absorbed 
drugs (Chong et al., 1996; Yee, 1997). The limitation is probably ascribed to the 
relatively lower expression of absorption transporters in Caco-2 cell than the in vivo 
enterocyte (Sun et al” 2002). 
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In view of the above and in considering the limitations of other in vitro 
absorption models, Caco-2 model is preferred for studying the transport mechanism 
of drugs. 
1.7 Aims of the study 
In summary, Green tea and hawthorn are chosen for the current study since 
they are the two most popular T C M containing abundance of active flavonoids. 
Although the health beneficial effects of G T C (EGC, EC, E G C G , ECG) and HF 
(EC, IQ, HP) are well documented, there is a lack of information concerning the 
extent of their in vivo uptake and the related oral absorption mechanism. The present 
study aims to characterize the absorption mechanism of the above active 
components using in vitro Caco-2 cell monolayer model. The specific objectives of 
the current study are: 
1. To perform bi-directional transport study of the G T C and HF using 
Caco-2 cell monolayer model. 
2. To examine the possible involvement of active transporters during the 
transport of G T C and HF. 
3. To identify the possible metabolites generated during the absorption of 
the G T C and HF using Caco-2 cell model. 
4. To explore any potential additive effect on the absorption of each of the 
active ingredients from green tea and hawthorn. 
5. To investigate the effect of the matrix in the plant extract on the 
absorption of the active ingredients from green tea and hawthorn. 
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Chapter Two 
Transport mechanism of green tea catechins 
2.1 Introduction 
It has been well documented that green tea catechins, a subgroup of 
flavonoids, exhibit beneficial effects on human health. They possess radical 
scavenger (Uimo et al., 2002), anti-oxidative (Miyazawa, 2000), cardiovascular 
(Duffy et al., 2001) and anti-carcinogenic activities (Katiyar and Mukhtar, 1996). 
Animal pharmacokinetics study indicated that the bioavailabilities of G T C 
are relatively low, and the extent of oral absorption for the G T C varies. The non-
gallated catechins generally have higher bioavailability (31.2% and 13.7% for 
epicatechin (EC) and epigallocatechin (EGC) respectively) than that of gallated-
catechins (0.1% for epigallocatechin gallate (EGCG)) (Chen et al., 1997). Human 
studies supported the observation of the low oral bioavailability of G T C (Chow et 
al., 2001). Significant presystemic elimination was proposed for the cause of the 
poor bioavailability of G T C (Chen et al., 1997, Zhu et al., 2000). In addition, it was 
reported that the hepatic elimination did not play an important role for the low oral 
bioavailability of EC, E G C and E G C G (Cai et al., 2002). Therefore, the current 
study is proposed to explore the intestinal absorption mechanism of the major GTC, 
EC, EGC, E G C G and ECG, to find out whether intestinal epithelium is a 





(-)-Epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, (-)-
epigallocatechin gallate, verapamil, lucifer yellow, diltiazem, ketoconazole, 
phosphate buffer tablets, sulfatase (S 9754), fisetin (used as internal standard for 
sample analysis of EC with hydrolysis treatment) were purchased from Sigma 
Chemical Co., USA. M K 571 was supplied by Biomol research laboratories Inc. 
USA. Isoquercitrin, used as internal standard for determining concentration of EC 
and E G C G for samples without hydrolysis treatment, was from Carl Roth, Germany. 
Propranolol was bought from Synco. Quinidine was obtained from Fluka, 
Switzerland. Quinine was purchased from B D H , England. HPLC grade methanol 
and acetonitrile were from Labscan Asia Co. Ltd. Thailand. Other chemical reagents 
used were at least of analytical grade. 
2.2.2 Materials for cell culture 
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), 
0.05% Trypsin-Ethylenediaminetetraacetic Acid (EDTA), Penicillin-Streptomycin, 
and non-essential amino acids were obtained from GibcoBRL, Life & Technologies, 
USA. Collagen type I, sodium pyruvate were purchased from Sigma Chemical Co., 
USA. Caco-2 cells were obtained from the American Type Culture Collection. Six-
well transwell® plates (0.4 |im pore size, 4.71 cm�，polycarbonate filter, Co star 




The H P L C system is composed of Waters 2690 separation module, Waters 
996 photodiode array (PDA) detector and Waters 464 pulsed electrochemical 
detector (ECD). Fluorescence was measured by fluorescence spectrophotometer 
(Model F2000, Hitachi, Japan). 
HPLC/Mass spectrometry was performed on API 2000 Triple Quadmpole 
LC/MS/MS spectrometer. Two Perkin-Elmer PE-200 series micro-pumps and auto-
sampler (Perkin-Elmer, Norwalk, CT, USA) were used to perform the analysis. 
2.3 Methods 
2.3.1 Analytical methods 
2.3.1.1 Analytical methods for validation of Caco-2 model 
2.3.1.1.1 Fluorescence analysis of lucifer yellow 
Lucifer yellow was measured at 424 nm of excitation wavelength and 525 
nm of emission wavelength. 
2.3.1.1.2 HPLC analysis of propranolol 
BDS CI8 reversed phase column (4.6 m m I.D. x 250 m m , Sjum, Thermo 
Hyersil) was employed. The mobile phase consisted of 40% acetonitrile and 60% of 
25 m M phosphate buffer (pH2.5). The flow rate was set at 1.0 ml/min and the U V 
measurement was conducted at 290 nm. 
39 
— Chapter Two 
2.3.1.1.3 HPLC analysis of verapamil 
A 150 |il of the sample was spiked with 10 |il of 20 |ig/ml diltiazem (used as 
an internal standard). Verapamil and diltiazem were separated with B D S CI8 
reversed phase column (4.6mm I.D. x 250 m m , Sjum, Thermo Hyersil) and eluted by 
the following mobile phase system. The gradient began with 45% acetonitrile and 
55% phosphate buffer (pH 2.5) and maintained for 7 min, then was linearly changed 
to 80% acetonitrile and 20 % phosphate buffer in 3 minutes, followed by 
maintaining this percentage till 13 min. After that, the gradient was changed back to 
45% acetonitrile and 55% phosphate buffer in 1 minute, and equilibrated for another 
minute. The flow rate of the mobile phase was 1.0 ml/min and wavelength of 278 
n m was chosen for quantitation analysis of verapamil. 
2.3.1.1.4 HPLC analysis of quinidine 
B D S CI8 reversed phase column (4.6mm I.D. x 250 m m , 5|Lim, Thermo 
Hyersil) was chosen for separation. The mobile phase for elution is composed of 
11% solvent A (acetonitrile) and 89% solvent B (water: triethylamine 11:1, v/v, 
adjusted to pH 2.5). The flow rate was set at 1 ml/min. A 150 jil sample was spiked 
with 25 |il of 5 fig/ml of quinine as an internal standard. All samples were analyzed 
by P D A detector at 290 nm. 
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2.3.1.2 Analytical methods for samples contained GTC 
2.3.1.2.1 HPLC analysis for each GTC 
O D S reversed-phase column (4.6mm I.D. x 250 m m , 4.5|Lim, Beckman) was 
chosen for separation. A 175 \il sample was spiked with 25 iil of various internal 
standards as described in Table 2.1. E C D with potential set at 1000 m V was used for 
the detection of GTC. The related H P L C conditions used for each compound 
analysis are listed in Table 2.1. 
Table 2.1 Various HPLC conditions and internal standards (IS) used for 
the analysis GTC 
Percentage of each eluent (%) 
Compounds Flow rate Time Methanol ACN Buffer ^ IS 
(min) 
1 ml/min 0 0 10 % IQ 
15 80 0 20 (5 |Lig/ml) 
or Fisetin ^ 
20 0 10 90 (2 iLig/ml) 
E ^ 1 ml/min 0 0 5 ^ ^ 
20 0 15 85 (2-5 昭/ml) 
25 0 5 95 
EGCG 1 ml/min 0 0 10 % IQ 
20 5 25 70 (5 叩/ml) 
22 0 10 90 
EOT 1 ml/min 0 0 10 ^ EC 
20 5 25 70 (2.5 昭/ml) 
22 0 10 90 
a: 25 m M NaH2P04 (pH2.5) 
b: used as internal standard for samples with hydrolysis process. 
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2.3.1.2.2 Preparation of calibration curves for each GTC 
Primary stock solutions of each G T C were prepared by dissolving accurately 
weighed quantities of each standard compound in methanol to reach 2 mg/ml. The 
10 |Lig/ml working stock solution of each G T C was obtained by dilution of the 
primary stock solution with aqueous solution (pH=2.5) containing 0.125% ascorbic 
acid. The calibration curve of each G T C was prepared by serial dilution with 
0.125% ascorbic acid aqueous solution (pH2.5) from working stock solution to reach 
1000 ng/ml, 500 ng/ml, 200 ng/ml, 100 ng/ml, 50 ng/ml, 20 ng/ml, and 10 ng/ml, 
respectively. 
2.3.1.2.3 HPLC/MS analysis of samples containing mixtures of four GTC 
B D S C18 reversed phase column (4.6mm I.D. x 250 m m , 5jLim, Thermo 
Hyersil) was used for separation. A 175 jil sample was spiked with 25 [d of internal 
standard (5 jig/ml of IQ) and injected into HPLC for analysis. The gradient began 
with 10% methanol and 90 % water with 0.04% formic acid (pH3.0) and was 
changed linearly to 60 % methanol and 40% water in 15 minutes and remained this 
percentage for 5 minutes. Then the gradient was changed back to 10% methanol and 
90 % water in 2 minutes and equilibrated for 3 minutes at this percentage. A flow 
rate of 1 ml/min was selected. A 20% eluent was introduced into mass spectrometer 
for analysis and the other 80 % was splitted off. 
Negative mode was set for analysis. The other mass spectrometer working 
parameters were as follows: orifice voltage, -82V; ring voltage, -230V; nebulization 
gas, 23psi; auxiliary gas, 40psi; nebulizer temperature, 400 
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2.3.1.2.4 Preparation of calibration curves for samples containing GTC 
mixture 
Primary stock solutions of G T C were prepared by dissolving accurately 
weighed quantities of each standard compound in methanol to reach 2 mg/ml. The 
working stock solutions with 10 jug/ml of the each G T C as a mixture were obtained 
by dilution of the primary stock solution with aqueous solution (pH=2.5) containing 
0.125% ascorbic acid. The prepared stock solutions were stored under —80。C. The 
calibration curves were prepared by serial dilution of the working stock solution 
with 0.125% ascorbic acid aqueous solution (pH2.5) to reach 500 ng/ml, 200 ng/ml, 
100 ng/ml, 50 ng/ml, 20 ng/ml, and 10 ng/ml of each compounds in the final 
mixture, respectively. 
2.3.1.2.5 Validation of the HPLC methods 
Validation of the developed HPLC methods was conducted by determining 
the intra-day, inter-day accuracy, and precision at high, middle and low 
concentration levels. The precision of the assay was defined as the relative standard 
deviation (RSD) and the accuracy was the percentage difference of the determined 
concentration from nominal value. % Difference =[(determined —— nominal) / 
nominal] x 100. The linearity of calibration curve was examined as well. 
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2.3.1.3 Identification of metabolites with HPLC/MS 
O D S reversed-phase column (4.6mm LD. x 250 m m , 4.5|Lim, Beckman) 
eluted with gradient at a flow rate of 1 ml/min was selected. For EC E G C G and 
ECG, the gradient began with 10% eluent A (acetonitrile) and 90% eluent B (0.04% 
formic acid), and was changed to 30% eluent A and 70% eluent B in 20 min, then 
was changed back to 10% eluent A and 90% eluent B in 2 min. Gradient for E G C 
started with changing from 5% of eluent A (acetonitrile) and 95% eluent B (0.04% 
formic acid) to 15% eluent A and 85% eluent B in 20 min, followed by being 
changed back to 5% eluent A and 95% eluent B in 5 min. 20% of eluent was 
introduced into mass spectrometer and the other 80 % was splitted off. 
Negative mode was set for analysis. The other mass spectrometer working 
parameters were set as follows: orifice voltage, -82V; ring voltage, -230V; 
nebulization gas, 23psi; auxiliary gas, 40psi; nebulizer temperature, 400 °C. 
Deprotonated molecular ions of the possible metabolites of each G T C including 
methylated, sulfate conjugate, glucuronidated conjugate, methylated sulfate 
conjugate and methylated glucuronidated conjugate were monitored. 
2.3.2 Determination of stability profile of GTC in phosphate buffer 
The stability study was carried out to choose an appropriate experimental pH 
for transport studies of the four GTC. 
Phosphate buffered saline plus (PBS+) was used as the transport buffer for 
the planned transport study in Caco-2 monolayer model. It was prepared by 
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dissolving a commercial available PBS tablet in 200 ml water, followed by 
supplementing with 90 |il of 2 M calcium chloride and 80 |LI1 of 1 M magnesium 
chloride. The pH value of the buffer was adjusted to pH 6.0, 6.8 or 7.4 respectively 
by 85% phosphoric acid. 
Methanol stock solution of each G T C with a concentration of 4 mg/ml was 
diluted with PBS+ at pH 7.4, pH 6.3 and pH 6.0, respectively, to reach 10 jug/ml for 
each GTC. The prepared solutions were incubated in shaking water bath at 37°C. A 
150 |Lil of the sample was taken at different time intervals and the drug concentration 
was measured. The percentage of each compound remained was plotted against time 
to obtain the stability profile at different pHs. 
2.3.3 Cell culture 
Caco-2 cells from the American Type Culture Collection (ATCC) were 
cultured in D M E M 37°C, supplemented with 10% FBS and 1% non-essential amino 
acids, in an atmosphere of 5% CO2 and 90% relative humidity. Cell grown in 75 cm^ 
flasks was subcultured at 80-90% confluence by treating with 0.05 % Trypsin-
EDTA. The Caco-2 cell suspension was seeded in Transwell® inserts coated with a 




2.3.4 Validation of Caco-2 cell monolayer model 
2.3.4.1 Integrity of Caco-2 cell monolayer at pH 6.0 
The integrity of the monolayer was monitored by measuring the 
transepithelial electrical resistance (TEER) with an epithelial voltohmmeter during 3 
hours of transport study at pH 6.0. 
2.3.4.2 Permeability of paracellular and transcellular markers at pH 6.0 
Lucifer yellow and propranolol were commonly employed as a paracellular 
and a transcellular marker for determining the integrity of the Caco-2 monolayer 
model, respectively (Lennemas et al., 1997). Transport studies from apical side to 
basalateral side were performed with these two markers at pH 6.0 and the calculated 
apparent permeability coefficient of each marker was compared with that reported in 
the literature. 
2.3.4.3 Validation of the existence of P-glycoprotein (P-gp) transporter in 
Caco-2 monolayer model 
Quinidine is commonly regarded as a substrate of P-gp and verapamil is 
considered to be not only a substrate but also an inhibitor of P-gp (Litman, 2001). 
Ketoconazole is a very potent inhibitor of P-gp (Kim et al., 1999). Thus, in the 
present validation study, the bi-directional transport of the representative P-gp 
substrates, verapamil and quinidine, were first examined for the existence of efflux 
of these substrates. Then the bi-directional transport of verapamil was preformed in 
the presence of 10 fiM of ketoconazole to observe its inhibition effect on the efflux 
of verapamil (Kim et al., 1999). The bi-directional transport study of quinidine was 
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also carried out in the presence of 100 juM of verapamil to test its inhibition effect 
on the efflux of quinidine (Hunter et al., 1993). 
2.3.4.4 Cytotoxicity test 
The cytotoxicity test of green tea extract on Caco-2 cells was carried out 
since the transport study of green tea extract in Caco-2 cell model was involved in 
the experimental design. The components of the extract may contain other 
ingredients that could be cytotoxic to Caco-2 cells. In addition, loading 
concentration of the four G T C would be the highest in the form of green tea extract. 
Therefore, cytotoxicity of green tea extract should be examined prior to the formal 
transport experiment on Caco-2 cell model. 
M T T (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) is a 
tetrazolium salt that is cleaved by mitochondrial dehydrogenase of living cells to 
give a dark blue formazan product. Damaged or dead cells should show no reduced 
dehydrogenase activity (Mossman, 1983). The Caco-2 cells used for M T T test were 
seeded onto a 96-well plate at a seeding density of 5x 10^ cells per well in D M E M 
culture medium (Meaney et al., 2000). The cells were cultured at 37 °C for 24 hours. 
Subsequently, the culture medium was replaced with 150 |LI1 of green tea extract 
dissolved in PBS+ (pH6.0) at eight studied concentrations (3, 1.5, 0.75, 0.38, 0.19, 
0.094, 0.047, 0.023 mg/ml). Blank PBS+ (pH 6.0) was employed as a negative 
control. Then the 96-well plate was incubated at 37 °C for 3 hours. Thereafter, 20 |LI1 
of 5 mg/ml M T T solution in PBS was added to each well and the plate was 
incubated for another 4 hours. The solution in the wells was then removed. The 
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remained formazan crystals in the cells were dissolved in 200 jul of D M S O , followed 
by measuring its absorbance at 590 n m in a Kinetic microplate reader (Molecular 
Devices). The cytotoxicity of the extract was calculated as the percentage of the 
absorbance relative to control. 
2.3.5 Transport study of GTC using Caco-2 cell monolayer model 
2.3.5.1 Bi-directional transport experiment 
The prepared Caco-2 cell inserts were rinsed twice with PBS+ transport 
buffer and equilibrated at 37 °C with PBS+ buffer for 15 min before the transport 
experiment. In the absorption transport study, 1.5 ml of the compound solutions 
dissolved in PBS+ at appropriate concentrations were loaded at the apical (AP) side, 
called donor chambers, and 2.6 ml of blank PBS+ was placed at basolateral (BL) 
side, called receiver chambers. In the secretion transport, 2.6 ml of compound 
solution was added at B L side (donor chambers) and 1.5 ml of blank PBS+ was 
placed at the AP side (receiver chambers). Aliquots of 0.5 ml samples were taken 
from receiver chambers at different time intervals after loading (30, 60, 90, 120, 180 
min). After each sampling, the same volume of blank PBS+ was replaced to the 
receiver chambers to maintain a constant volume. 
2.3.5.2 Preparation of different dosing formulations of GTC 
2.3.5.2.1 Preparation of individual pure GTC solutions 
Individual pure G T C solutions were prepared by dissolving each of the pure 
G T C in the PBS+ transport buffer (pH6.0) to reach 50 ^ iM. 
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2.3.5.2.2 Preparation of cocktail 1 solution 
Cocktail 1 solution was prepared by mixing all of the pure G T C in the PBS+ 
transport buffer (pH6.0) to reach 50 |LIM for each compound. 
2.3.5.2.3 Preparation of green tea extract solution 
The extraction method is similar to that developed by Chen (Chen, 2000). In 
detail, tealeaves (100 g) were extracted twice with 2000 ml of boiling distilled water 
for 30 min. The collected water extract was filtered by gauze and concentrated by 
Rotavaper (Biichi) to 1000 ml. The concentrated water extract was then extracted 
three times with an equal volume of ethyl acetate. The combined ethyl acetate layer 
was concentrated with Rotavaper, followed by mixing with 50 g silica gel. The 
mixture was then loaded onto a column packed with 80 g silica gel beforehand, then 
eluted with chloroform: methanol (20:1) as mobile phase to remove caffeine and 
other impurities. The elution with 100 % methanol was conducted subsequently. The 
obtained methanol fraction was dried by Rotavaper and the residue was re-dissolved 
in water. The green extract was obtained by freeze-drying the water solution and 
was stored at 4 � C . 
Green tea extract loading solution for Caco-2 cell model study was prepared 
by dissolving green tea extract powder in the PBS+ transport buffer (pH 6.0) to reach 
2 7 6 |ag/ml. This solution was analyzed to contain 22.1 |Lig/ml (50 |LIM) of ECG, 14.6 
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L^ ig/ml (50 |LIM) of EC, 35.1 jug/ml (115 jiiM) of EGC, and 125 路/ml (274 |LIM) of 
E G C G . 
2.3.5.2.4 Preparation of cocktail 2 solution 
Cocktail 2 solution was prepared by dissolving the four pure G T C in the 
PBS+ transport buffer of pH 6.0 to make the final concentration of each G T C reach 
the same molar concentration as that in the G T C extract solution. 
The final concentrations of each G T C in the above four dosing formulations 
for the transport study in Caco-2 cell model were summarized in Table 2.2. 
Table 2.2 Preparation of different dosing formulations of GTC for 
transport study in Caco-2 monolayer model 
Individual Cocktail 1 Cocktail 2 Extract 
pure 
compounds 
Concentration in PBS+ (pH6.0) (|i M ) 
TC ^ ^ 50 50 
E G C 50 50 115 115 
E G C G 50 50 274 274 
E C G 50 50 50 50 
2.3.5.3 Sample treatment 
2.3.5.3.1 Samples for direct analysis 
The samples obtained from the Caco-2 cell model transport study were 
acidified with ascorbic acid solution, containing 1 % ascorbic acid and 0.28% H3PO4, 
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to reach pH 2.5 for stability consideration (Chen et al., 1998b; Chen et al., 2001). 
The volume ratio of sample to ascorbic acid was 150 : 25 (v/v). 
2.3.5.3.2 Samples for enzymatic hydrolysis treatment 
Aliquots of 100 |LI1 of the samples were added with 10 |LI1 of sodium acetate 
(2M) to adjust the pH to 5.0. A 20 jul sulfatase (40 U) was loaded. After incubation 
of the mixture for 30 min at 37 1 ml of acetone was employed for precipitation of 
the protein. The mixture was vortexed and then centrifuged at 13,000 rpm for 5 min 
and the supernatant was withdrawn and dried in the centrifuge concentrator. The 
residues were re-dissolved in 100 jjJ of phosphate buffer (pH 2.5) for HPLC analysis 
(Yang et al, 1998). 
2.3.5.4 Further investigation of the transport mechanism of GTC 
2.3.5.4.1 Inhibition transport of EC and EGC 
In order to identify the possible efflux transporters involved in the absorption 
process of the GTC, the bi-directional transport experiments were conducted in the 
presence of MK571, a typical M R P 2 inhibitor (Vaidyanathan and Walle., 2001; 
Walgren et al., 2000). A 50 )iM MK571 solution was preloaded at the apical side for 
20 min. The bi-directional transport studies were then performed in the presence of 
50 |iM of MK571 at the donor chambers. 
In addition, the bi-directional transport experiment was also performed in the 
presence of verapamil, a typical P-gp inhibitor, to evaluate the contribution of P-gp. 
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A 100 |iM verapamil solution was preloaded at both sides of the chambers for 20 
min, followed by conducting the bi-directional transport studies in the presence of 
100 |iM of verapamil at both sides of chambers. 
2.3.5.4.2 Transport mechanism of metabolites of EC and EGC 
The samples were taken from the receiver chambers at the end of the 
secretion transport experiment of EC and E G C in the absence and presence of 
inhibitors (verapamil and MK571). They were analyzed with HPLC/ECD or 
HPLC/MS and the chromatograms of the samples were compared to examine the 
effect of transport inhibitors on the transport of EC and E G C metabolites. 
2.3.5.4.3 Metabolic competition between EGC and the other GTC 
In the secretion transport studies of E G C in the forms of individual pure 
compound, cocktail 1 and cocktail 2, samples were taken from the apical side, the 
receiver chamber, at the end of the experiment and were analyzed by HPLC/MS. 
The peak area ratios of metabolites versus parent compound in the HPLC/MS 
chromatogram were compared among different dosing formulations to examine 
whether competitive metabolism was involved. 
In order to evaluate the contribution of each G T C in the metabolic 
competition, the secretion transport with the following combinations were 
performed: 1) 50 ^ M of E G C and 50 ^ M of EC; 2) 50 |iM of E G C and 50 ^ iM of 
EGCG; 3) 50 i^M of E G C and 50 |LIM of ECG; 4) 50 JUM of E G C served as the 
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control. The samples taken at the end of experiment from the receiver chambers 
were analyzed with HPLC/MS. The peak area ratios of metabolites versus parent 
compound were compared between each of the above combinations and the control. 
2.3.6 Calculation 
The apparent permeability coefficient (Papp) was calculated according to the 
following equation: Papp = [(dC/dt xV)]/(A x C), where "dC/dt" is the change of the 
drug concentration in the receiver chambers over time, “V，，is the volume of the 
solution in the receiver chambers (cm); "A" represents the membrane surface area 
(cm^); "C" is the initial concentration in the donor chambers. Samples were taken at 
30, 60, 90, 120, 150, 180 min. 
Efflux ratio or secretion ratio is commonly used to assess the extent of efflux 
(Liang et al., 2000; Eagling et al., 1999; Makhey et al., 1998). The equation is 
shown below: 
P--(画"） 
Efflux ratio = T ； 7 
P卿姻(画"） 
Where Papps,oA is the mean of the permeability coefficient obtained 
from basalateral to apical direction,户叩万{mean) is the mean of the permeability 
coefficient obtained from apical to basalateral direction. 
To evaluate the amount of the compound remained after transport 





The final amount of the parent compound found in both donor and receiver chamber 
X 100% 
The initial amount of the parent compound loaded in the donor chamber 
2.3.7 Data analysis 
Results were presented as mean 士 SD (n=3). Statistical significant difference 
between two groups was evaluated by Student's t test. Statistical significant 
difference among more than two groups was evaluated by one-way A N O V A , and 
the multiple comparison with Tuckey's test was used to determine the difference 
between each pair of means. P<0.05 was considered significant for all tests. 
Comparison of the transport profile was conducted between individual pure 
catechins (50 |iM) and cocktail 1, the mixture of four pure G T C with the same molar 
concentration of 50 jiM, in order to discover the potential additive effect among the 
four G T C on the transport process. Comparison of the transport profile between 
cocktail 2 and green tea extract was intended to study the possible effect of the 
matrix in the extract (other co-occurring components in extract in addition to GTC) 




2.4.1 Validation of the HPLC methods 
The calibration curves of the four G T C were linear over the studied 
concentration ranges. The intra-day, inter-day precision and accuracy of the four 
studied catechins at high, middle, low concentrations were all within 10% (Table 
2.3, Table 2.4). These results indicated that the developed HPLC methods were 
suitable for the sample analysis of the current study. 
2.4.2 Stability of the GTC 
As shown in Figure 2.1, EC and E C G were stable under the three different 
pH conditions, while the stability of E G C and E G C G was pH-dependent. The more 
acidic condition it was, the more stable E G C and E G C G were. Few transport studies 
in Caco-2 model was performed below pH 6.0 from previous research finding. In 
view of the viability of Caco-2 cells and the stability of the studied compounds, pH 
6.0 was thus chosen for the current transport studies. 
2.4.3 Extract of green tea leaves 
A 10 g dry powder of green tea extract was obtained from 100 g of the dry 
green tea leaves. The powder was analyzed to contain 12.7% of EGC, 5.3% of EC, 















































































































































































































































































































































































































































































































































































































































































































































































































































































Stability of green tea catechins in PBS+ (pH=7.4) 
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2.4.4 Validation of Caco-2 model 
2.4.4.1 Integrity of Caco-2 cell monolayer 
2 
The TEER values were found to maintain at above 1319 ohm-cm before and 
after the transport studies, indicating that the integrity of the Caco-2 cell monolayer 
at pH 6.0 was not damaged. 
2.4.4.2 Permeability of paracellular and transcellular markers at pH 6.0 
As listed in Table 2.5, the apparent permeability coefficients of the two 
markers were all within the range of the reported values from the previous literature 
(Yee, 1997; Irvine et al., 1999), indicating that the paracellular and transcellular 
transport pathway was not affected at pH 6.0. 
Table 2.5 Apparent permeability coefficients of paracellular and 
transcellular marker at pH 6.0 (n=3) 
Marker Experimental value Reference value 
Papp (X 10 -6 cm/s) 
Lucifer yellow 0.163 ±0.012 0.1-0.7' 
Propranolol 22.5 士 2.9 27.5 ^  
a: Irvine et al., 1998 
b: Yee, 1997 
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2.4.4.3 Validation of P-glycoprotein 
A 10 jiM ketoconazole and 100 jiM verapamil solutions are generally 
considered to be able to provide sufficient inhibition of P-gp substrates in the Caco-2 
cell model (Kim et al., 1999; Hunter et al., 1993). As shown in Figure 2.2 A, 2.2 B, 
verapamil and quinidine exhibited efflux that could be effectively inhibited by 
ketoconazole and verapamil respectively. These results confirmed the existence of 
P-gp in our developed Caco-2 monolayer model. 
2 T — — — — — — 一 一一――—^^^^ m A P to BL 
-T- 圃 BLtoAP 
伊as^'tp^，丨社：角丨 T I i 1.5 ^ ^ i 
c * 、： I •壩 
I T 丨 〜 . I 
？ 1 一 "：1 I H 
I 0.5 —— 〖I , , | _ I I 
0 J j J I I 
Without ketoconazole With ketoconazole 
Figure 2.2 A Bi-directional transport profile of a typical P-gp substrate, verapamil, in 
the presence and the absence of P-gp inhibitor, ketoconazole (n=3). 
Papp value (AP to BL) of verapamil in the absence of ketoconazole is 
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Figure 2.2 B Bi-directional transport profile of typical P-gp substrate, quinidine, in 
the presence and the absence of P-gp inhibitor, verapamil (n=3). *: Papp 
value (AP to BL) of quinidine in the absence of verapamil is 
significantly different from that (AP to BL) in the presence of 
verapamil (P<0.05). 
2.4.4.4 Cytotoxicity test 
As shown in Figure 2.3, in comparison with the negative control, there is no 
decrease in the percentage of absorbance observed. These results indicated that there 
should be no cytotoxicity effect of green tea extract on Caco-2 cells at a 












































































































































































































2.4.5 Transport study of GTC 
2.4.5.1 Bi-directional transport of individual pure GTC 
In this study, obvious efflux transport was observed for EC. In the absorption 
transport study, limited amount of EC was found at the receiver chambers. The Papp 
value for A P to B L direction transport was 1.39士0.08x1 CT? cm/sec, which is 
comparable to those values of paracelluar markers, such as lucifer yellow as 
described in Table 2.5. In contrast, the secretion transport of EC was much more 
efficient with a P — value of 29.96±1.23x10—7 cm/sec, which is 20 fold higher than 
that of its absorption transport (Figure 2.4). 
For the bi-directional transport study of EGC, poor Papp was found in its 
absorption transport. A medium extent of efflux transport of E G C was observed with 
an efflux ratio of 5.18 (Table 2.6). 
In the case of E G C G and ECG, minor or no significant efflux was observed 
from their bi-directional transport, with efflux ratios of 4.02 for E C G and 1.83 for 
E G C G , respectively (Table 2.6). 
Comparing the efflux ratios of the four GTC, EC was observed to exhibit the 
most intensive efflux. EGC, with one more hydroxyl group at 5' position than EC, 
showed a medium extent of efflux, then followed by E C G and E G C G , which have 
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an extra gallate group than EC and E G C respectively, in descending order of extent 
of efflux. 
Table 2.6 Papp (mean 士 SD) and efflux ratio of four GTC in the presence 
and absence of MK571 (n=3). 
Transport in the absence of MK571 Transport in the presence of MK571 
^ P a p p i S D (xlO"^ cm/sec) Efflux Papp 士 SD (xlO"^ cm/sec) Efflux 
— ratio ratio AP to BL BL to AP AP to BL BL to AP 
EC 1.39±0.082 29.96±1.24 21.55 3.50±0.22 * 5 . 2 5 ± 0 . 3 9 # L ^ 
EGC 1.49 士0.13 7.72±0.43 5.18 3.31±0.21 * 3.33±0.21 # 1.01 
ECG 0.96±0.15 3.86士0.73 4.02 N/A N/A N/A 
EGCG 0.83±0.24 1.52±0.15 1.83 N/A N/A N/A 
N/A: not applicable 
*： Papp values (AP to BL) in the absence of MK571 is significantly different from 
that (AP to BL) in the presence of M K 571 (P<0.05). 
#: Papp values (BL to AP) in the absence of MK571 is significantly different from 
that (BL to AP) in the presence of M K 571 (P<0.05). 
Table 2.7 Recovery of the four GTC after the transport experiment (n=6). 
Compounds Recovery (%) 
^ 93.1±1.9 
EC 94.9+4.7 
E G C G 91.9±3.7 
E C G 86.8±6.3 
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Figure 2.4 Bi-directional 
apparent permeability coefficients of the four G T C 
(n=3). 
#: There are significant differences in Papp values (AP to BL) among 
the four G T C (P<0.05). 
*： There are significant differences in Papp values (BL to AP) among 
the four G T C (P<0.05). Table 2.8 Multiple comparison of Papp (BL to AP) between every two GTC. 
EC E ^ E r a E G C G 
EC - * * * 
E G C * - * * 
E C G * * - * 
E G C G * * * -
*: The values are significantly different from each other (P<0.05). 
-：The values are not significantly different from each other (P>0.05). 
Table 2.9 Multiple comparison of Papp (AP to BL) between every two GTC. 
^ E ^ E T O E G C G 
^ - - * * 
E G C - - * * 
E C G * * - -
E G C G * * - -
*: The values are significantly different from each other (P<0.05). 
-:The values are not significantly different from each other (P>0.05). 
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2.4.5.2 Bi-directional transport of GTC in different dosing formulations 
2.4.5.2.1 Absorption transport profile of GTC in different dosing formulations 
As presented in Figure 2.5, 2.6，2.7, 2.8, there was no significant difference 
on Papp of absorption transport for each G T C between individual pure compound 
forms and cocktail 1, indicating that there might not be additive effect among the 
four G T C on the absorption of each GTC. 
As described in Figure 2.9, 2.10, 2.11, 2.12, the Papp from absorption 
transport of each G T C was similar in cocktail 2 and extract form, demonstrating that 
the matrix components had no effect on the absorption of each GTC. 
2.4.5.2.2 Secretion transport profile of GTC in different dosing formulations 
In the secretion transport, the situations were much more complicated. For 
EC, the Papp value of B L to AP transport decreased slightly from 29.95±1.24x10-7 
cm/sec for individual pure EC to 25.57+2.24x10'^ cm/sec for EC in cocktail 1 
(Figure 2.5). 
For EGC, the Papp value of BL to AP was enhanced from 7.72±0.44xl0-7 
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Figure 2.5 Bi-directional transport of EC in individual pure compound form and 
cocktail 1 of G T C (n二3). *: Papp value (BL to AP) of EC in the 
individual form is significantly different from that in Cocktail 1 
(P<0.05). 
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Figure 2.6 Bi-directional transport of E G C in individual pure compound form 
and cocktail 1 of G T C (n=3). *: P — value (BL to AP) of E G C in the 
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Figure 2.7 Bi-directional transport of E C G in individual pure compound form 
and cocktail 1 of G T C (n=3). 
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Figure 2.8 Bi-directional transport of E G C G in individual pure compound 
form and cocktail 1 of G T C (n=3). *: Papp value (BL to AP) of 
E G C G in the individual form is significantly different from that in 
Cocktail 1 (P<0.05) 
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Figure 2.9 Bi-directional transport of EC in cocktail 2 of G T C and 
extract of green tea (n=3). N. A.: not available. 
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Figure 2.10 Bi-directional transport of E G C in cocktail 2 of G T C and 
extract of green tea (n=3). N. A.: not available. 
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Figure 2.11 Bi-directional transport of E C G in cocktail 2 of G T C and extract 
of green tea (n=3). N. A.: not available. 
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Figure 2.12 Bi-directional transport of E G C G in cocktail 2 of G T C and 
extract of green tea (n=3). N. A.: not available. 
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For E G C G , marginal increase of permeability of secretion transport in the 
cocktail 1 was found after comparing the secretion transport of individual pure 
compounds with cocktail 1 (Figure 2.7, 2.8). The overall Papp values of the secretion 
transport of E C G and E G C G were fairly low and comparable to those of paracelluar 
markers. 
Surprisingly, in the secretion transport study of extract, loading the green tea 
extract to basalateral side led to significant dropping of TEER value (from about 
2 2 
1300 n- cm to 650 Q- cm ) after only half an hour, indicating that the damage of 
integrity of the monolayers might have occurred. However, such damage was not 
observed in absorption transport of the extract after loading the same concentration 
of extract to the apical side of the chamber. The observation might reflect that the 
matrix existed in the green tea extract could have exerted potential cellular toxicity 
in the basalateral side of the Caco-2 cell. 
2.4.5.3 Identification of metabolites of each GTC formed during the transport 
in Caco-2 cell model 
EC 
As shown in Figure 2.13 A, in the secretion transport experiment, several 
metabolites (Ml, M2, M3) of EC were observed in the receiver chambers by 
HPLC/ECD as early as 30 min and remained increased in amount for the following 
2.5 hours. However, none of the above metabolites was found in the receiver 
chambers during the absorption transport experiment (Figure 2.13 B). 
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In order to identify the type of the metabolites observed, enzymatic 
hydrolysis and HPLC/MS were employed. Hydrolysis of the apical samples after 
basalateral loading of EC with pure sulfatase resulted in decreased amount of M l 
and increased amount of EC (Figure 2.14). Thus, M l was identified as the sulfate 
metabolite of EC. The deprotonated molecular ions of EC (m/z, 298) and its possible 
metabolites (EC sulfate conjugate (m/z, 369), methylated E C (m/z, 303), methylated 
EC sulfate conjugate (m/z, 383), EC glucuronidated conjugate (m/z, 465) and 
methylated EC glucuronidated conjugate (m/z, 479)) were targeted by mass 
spectrometry with electrospray ionisation in a negative mode. The results indicated 
that the metabolites of EC were sulfate conjugate, methylated EC, and methylated 
sulfate conjugate of EC (Figure 2.15 A). Whereas, EC glucuronidated conjugate and 
methylated EC glucuronidated conjugate were not observed. The mass spectrum was 
only available for EC sulfate conjugate that was the major metabolite of EC, since 
the concentrations of the other metabolites were too low to perform full scanning. 
As shown in Figure 2.16, molecular ion of EC sulfate conjugate was at m/z 369. The 
predominant product ion of EC sulfate conjugate was its deprotonated aglycone, EC, 
at m/z 289. Combining the results obtained from HPLC/MS with the observation 
from HPLC/ECD chromatogram, M 2 and M 3 were identified as the methylated 
sulfate conjugate of EC and methylated EC respectively based on their chemical 
structures and relative retention times. 
The basalateral samples after apical loading were also applied to HPLC/MS 
and the type of metabolites formed were confirmed to be the same as that from the 
apical samples after the basalateral loading (Figure 2.15 B). As to the relative 
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amount of metabolites formed, the results were consistent with those observed with 
HPLC/ECD detector i.e. fewer amount of metabolites was formed in the basalateral 
side in the AP to B L transport experiment 
In addition, metabolites were also observed in the donor chambers in both 
absorption and secretion transport studies (Appendix I). 
EGC 
LC/MS analysis using selective ion monitoring mode (SIM) targeted at the 
deprotonated molecular ion of E G C (m/z 305) and possible metabolites of EGC, 
which include sulfate conjugate of E G C (m/z 385), methylated E G C (m/z 319), 
methylated sulfate conjugate of E G C (m/z 399), E G C glucuronidated conjugate 
(m/z, 481) and methylated E G C glucuronidated conjugate (m/z, 495). The results 
confirmed the occurrence of sulfate conjugate of EGC, methylated E G C and 
methylated sulfate conjugate of E G C at the apical side in secretion transport (Figure 
2.17 A), while no E G C glucuronidated conjugate and methylated E G C 
glucuronidated were found in the present study. Similar to EC, none of the above 
metabolites was found at the receiver chamber from absorption transport with 
LC/MS analysis (Figure 2.17 B). Small amount of above metabolites was observed 
in donor chambers in both absorption and secretion transport (Appendix II). 
EGCG and ECG 
Several metabolites were found at the apical side in secretion transport of 
E G C G and ECG. Identification of the metabolites with LC/MS using SIM showed 
that there were methylated E G C G (m/z 471), sulfate conjugate of E G C G (m/z 537) 
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and methylated sulfate conjugate of E G C G (m/z 551) formed in the apical side after 
loading the E G C G in the basalateral side (Figure 2.18 A). No glucuronidated 
conjugate of E G C G (m/z, 633) and methylated E G C G glucuronidated conjugate 
were detected in the samples. For ECG, there were marginal amount of methylated 
E C G (m/z 455), sulfate conjugate of E C G (m/z 521) and methylated sulfate 
conjugate of E C G (m/z 535) formed in the apical side after the basalateral loading of 
E C G (Figure 2.19 A). However, no glucuronidated conjugate of E C G and 
methylated glucuronidated conjugate of E C G were detected in the above samples. 
Similarly, none of the above metabolites was observed at the receiver chambers in 
absorption transport of both E G C G and E C G (Figure 2.18 B, 2.19 B). Marginal 
amount of metabolites of E G C G and E C G was observed in donor chambers in both 
absorption and secretion transport (Appendix III, IV). 
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loading and apical sampling in the presence of verapamil. (D) Basalateral 
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Figure 2.18 LC/MS chromatograms of samples taken from the receiver chambers at the 
end of the transport experiments of EGCG. (A) Basalateral loading and 
apical sampling. (B) Apical loading and basalateral sampling. EGCG: 
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conjugate. Me-EGCG: methylated epigallocatechin gallate. Me-EGCG-
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2.4.6 Further investigation of the transport mechanism of GTC 
2.4.6.1 Inhibition transport of EC and EGC 
As shown in Table 2.6 and Figure 2.20, MK571 almost completely inhibited 
the efflux of EC, which confirmed the previous finding from Vaidyanathan and 
Walle that EC is the substrate of M R P 2 (Vaidyanathan and Walle, 2001). The 
presence of MK571 inhibited the directional transport of E G C as well (Figure 2.21). 
A 100 |iM verapamil could confer a much less inhibition to the efflux of EC, in 
comparison with that provided by M K 571. It seems that M R P 2 inhibitor could 
inhibit the efflux of EC and E G C more than P-gp inhibitor. This result may indicate 
that EC and E G C might interact more preferentially with M R P 2 rather than with P-
gP-
2.4.6.2 Transport mechanism of metabolites of EC and EGC 
As demonstrated in Figure 2.13 C and D, the presence of MK571 
dramatically decreased the formation of all the identified metabolites of EC, whereas 
the presence of verapamil barely had effect on the transport of these metabolites. 
Therefore, it is suggested that the metabolites of EC were the substrates of MRP2. 
Similarly, transport of metabolites of E G C was also inhibited by MK571 (Figure 
2.22), indicating that the metabolites of E G C were the substrate of M P R 2 as well. 
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Figure 2.20 Bi-directional transport of E C in the presence of various inhibitors (n=3). 
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Figure 2.21 Bi-directional transport of E G C in the presence of various inhibitors (n=3). 
#: Papp value (AP to BL) of E G C in the presence of M K 571 is significantly 
different from that (AP to BL) in the absence of any inhibitors. * : Papp value 
(BL to AP) of E G C in the presence of M K 571 is significantly different from 
that (BL to AP) in the absence of any inhibitors (P<0.05). 
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2.4.6.3 Metabolic competition between EGC and the other GTC 
Comparison of transport profile of E G C among its different dosing 
formulations (individual pure compound, mixture in cocktail 1 and cocktail 2) 
revealed that the extent of efflux of E G C increased in secretion transport by the two 
cocktail formulations. 
The underlying mechanism was discovered by determining the amount of 
metabolites of E G C by LC/MS. From the LC/MS chromatogram in Figure 2.23, 
major metabolites of E G C formed in the secretion transport study were E G C sulfate 
conjugate and methylated E G C sulfate conjugate. For samples from cocktail 1 and 
cocktail 2, the amount of two metabolites declined greatly and the methylated E G C 
sulfate conjugate was decreased almost below detection limit of LC/MS, while the 
amount of E G C was increased accordingly. To quantify the change of the amount of 
E G C and its metabolites, the peak area ratio of metabolite to E G C was utilized as an 
index. As summarized in Figure 2.24, dosing with cocktail 1 reduced the peak area 
ratios substantially, and dosing with cocktail 2 resulted in further reduction. These 
data demonstrated that different dosing formulations could affect the formation of 
E G C metabolites. 
Identification of the metabolite studies suggested that other catechins (EC, 
EGCG, ECG) might share the same metabolic pathways as E G C and generate 
mainly sulfated and methylated metabolites. Thus, metabolic competition between 
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the four green catechins could be the cause of a decreased amount of E G C 
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Figure 2.23 LC/MS chromatograms (targeting molecular ions of E G C and its 
metabolites) of samples taken from the receiver chambers at the end of the 
transport experiments. (A) Basalateral loading of individual E G C and apical 
sampling. (B) Basalateral loading of cocktail 1 and apical sampling. (C) 
Basalateral loading of cocktail 2 and apical sampling. EGC: 
epigallocatechin. EGC-sulfate: epigallocatechin sulfate conjugate. Me-EC-
sulfate: methylated epigallocatechin sulfate conjugate. IS: internal standard. 
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1, and cocktail 2) on the formation of the E G C metabolites in the B L to 
A P transport of E G C (n=3). *: The amount of E G C sulfate conjugate 
formed at apical side during secretion transport of cocktail 1 and 
cocktail 2 is significantly from that during secretion transport of 
individual EGC. #: The amount of methylated E G C sulfate conjugate 
formed at apical side during secretion transport of cocktail 1 and 
cocktail 2 is significantly from that during secretion transport of 
individual E G C (P<0.05). 
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2.4.6.4 Contribution of GTC on the metabolism of EGC 
As illustrated in Figure 2.25, 2.26, combination of 50 ^ M of EC with 50 p M 
of E G C reduced the formation of both E G C sulfate conjugate and methylated E G C 
sulfate conjugate. Mixture of 50 of |LIM of E C G or E G C G with E G C mainly reduced 
the formation of methylated E G C sulfate conjugate with a little inhibition of 
generation of E G C sulfate conjugate. 
The above results together with the observation from individual E G C and 
cocktail 1 confirmed the contribution of EC, ECG, and E G C G to the competitive 
metabolism during secretion transport of the cocktail 1. 
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Figure 2.25 LC/MS chromatograms (targeting E G C and its metabolites) of samples taken 
from receiver chambers at the end of the transport experiment. (A) Basalateral 
loading of single E G C and apical sampling. (B) Basalateral loading of EGC+EC 
and apical sampling. (C) Basalateral loading of E G C + E G C G and apical 
sampling. (D) Basalateral loading of E G C + E C G and apical sampling. (E) 
Basalateral loading of cocktail 1 and apical sampling. EGC: epigallocatechin. 
EC: epicatechin. EGCG: epigallocatechin gallate. ECG: epicatechin gallate. 
EGC-sulfate: epigallocatechin sulfate conjugate. Me-EC-sulfate: methylated 
epigallocatechin sulfate conjugate. IS: internal standard. 
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Figure 2.26 Effect of different combinations of G T C on the formation of the 
E G C metabolites in its B L to A P transport (n=3). *: The amount of 
E G C sulfate conjugate formed at apical side during secretion 
transport of various combinations and cocktail 1 is significantly 
different from that during secretion transport of individual EGC. #: 
The amount of methylated E G C sulfate conjugate formed at apical 
side during secretion transport of various combinations and cocktail 
1 is significantly different from that during secretion transport of 




2.5.1 Stability of the four GTC 
Although there was 85-90% of E G C and E G C G left in PBS+ (pH6.0) at 37°C 
after 2 hours of incubation, the recovery of E G C and E G C G was above 90% in the 
3-hour transport study under the same condition. It seems that E G C and E G C G 
become more stable in the presence of the Caco-2 cells. Similar observation was 
reported previously, in which E G C G was found much more stable in the presence of 
HT-29 cells (Hong et al. 2002). The reason that the presence of the cells can 
improve the stability of E G C and E G C G needs further investigation. As the recovery 
of the four G T C in the transport studies was about 90%, the contribution of 
degradation could be considered minimum. The overall loss of the compound may 
be due to degradation, cell uptake, nonspecific binding as well as drug metabolism. 
2.5.2 Validation of Caco-2 cell model 
Transport studies using paracellular (lucifer yellow) and transcellular 
(propranolol) marker showed the experimental Papp values were within the range of 
reported values. This indicated that the model used in the present study is suitable 
for the investigation of both the paracellular and transcellular transport of the drugs. 
With respect to the existence of P-gp and MRP2, verapamil and quinidine which are 
the P-gp substrates exhibited efflux and EC which is the substrate of M R P 2 
(Vaidyanathan and Walle, 2001) also exhibited significant efflux in the current 
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developed Caco-2 cell. This indicated that the model developed by us is also suitable 
to study the efflux of the drugs. 
2.5.3 Bi-directional transport of GTC 
Previous animal and human pharmacokinetics studies showed that the 
bioavailability of the tea catechins was relatively low (Chen et al., 1997; Chew et al., 
2001; Warden et al, 2001), and the hepatic elimination was not demonstrated to be 
the major cause of such low bioavailability (Cai et al., 2002). Consistent with the 
previous in vivo data, the Papp values obtained in the current absorption transport 
study for the catechins were fairly small and comparable to those of the paracelluar 
markers (Yee, 1997; Irvine et al., 1999). This indicates that the tea catechins may be 
transported via paracellular pathway (Figure 2.27). The intercellular space which is 
responsible for paracellular transport of hydrophilic drags accounts for only 0.1-0.01 
% of the surface area of intestine (Barthe et al., 1999). Thus, paracelluar transport is 
commonly regarded as an inefficient absorption pathway for the drugs except for 
those with small molecular size. The relative poor permeability of the four catechins 
to traverse the intestinal epithelium may be a limiting factor for their absorption in 
the in vivo situation. 
During the absorption transport, G T C is transported mainly through 
epithelium tight junction, i.e. via paracellular pathway, which should not be 
influenced by the transporters located in the apical membrane of Caco-2 cell. 
Therefore, although E G C and EC are the substrates of MRP2, their absorption 
transport via paracellular pathway should not be mediated by MRP2. The increased 
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Papp (AP to BL) of EC and E G C in the presence of M K 571, shown in table 2.6, 
should be due to the inhibition of secretion transport of EC and EGC. However the 
extent of enhancement is marginal with Papp (AP to BL) comparable to that of 
paracellular marker. 
The secretion transport of E G C and EC, is mainly transported by carrier-
mediated transcellular pathway mediated by MRP2. In the presence of MK571, such 
active transport would be blocked. Due to their relative low lipophilicity (the 
aqueous solubility of EC and E G C are both above 5 mg/ml (solubility test by Sigma-
Aldrich Co., USA)), EC and E G C would prefer being transported paracellularly, 
which resulted in a Papp as low as that of the paracellular markers (Figure 2.22). 
The present Caco-2 cell model study showed that the four G T C possess 
similar Papp in their absorption transport. However, these results may not completely 
represent the permeability of the four G T C in the small intestine. One limitation of 
the Caco-2 cells model is that the Caco-2 cell monolayer is morphologically more 
similar to colon than small intestine. The Caco-2 cells may have much higher 
trans epithelial electrical resistance (TEER) than small intestine. Previous work 
showed that the paracellular markers exhibited much lower permeability by the 
Caco-2 cell model than that in small intestine (Barthe et al., 1999). 
It is believed that Papp of drugs transported paracellularly is inversely 
proportional to the molecular weight or size of the drug. However, the conjunction 
between Caco-2 cells might be too "tight" to differentiate the size differences of the 
drugs absorbed paracellularly. Thus, the size and molecular weight discrepancy 
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between non-gallated catechins (EC, with M . W . 290; EGC, with M.W.306) and 
gallated catechins (EGCG, with M . W . 458; ECG, M . W . 442) could not be 
distinguished in the Caco-2 cell model studies. 
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Figure 2.27 Schematic diagrams illustrating the bi-directional transport 
mechanism of four GTC. (Upper): Bi-directional transport of 
GTC in the absence of M K 5 7 L (Lower): Bi-directional 
transport of GTC in presence of MK571. 
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2.5.4 Structure related efflux 
In general, the reported M R P 2 substrates include glutathione conjugates 
[e.g., 2,4-dinitropheyl-S-glutathione, (DNP-SG) and Leukotriene C4 (LTC4)], 
glucuronide conjugates [e.g., estradiol 17-P-D-glufuronide (E2I7 P G)], sulfate 
conjugates of certain bile salts [e.g., taurolithocholate-3-sulfate (TLC-S)], and non-
conjugated organic anion (e.g., methotrexate) (Ito et al., 2001). Recently, a study on 
the relation between physicochemical property of methotrexate (MTX) analogs with 
their affinity to M R P 2 discovered that the affinity constants are closely correlated 
with the octanol/water partition coefficient (logP) and the balance of polar and non-
polar surface area are also required (Han et al., 2001). So far, the characterization of 
the chemical structures of M R P 2 substrates still seem to be too preliminary. The 
importance of our study was the discovery of the structural related efflux of GTC, 
which may provide more information on the relationships of M R P 2 and the 
chemical structures of their substrates. EC demonstrated extensively efflux mediated 
by MPR2. E G C with one more hydroxyl group at 5' position showed a medium 
efflux, suggesting 5'- O H group may decrease the affinity of E G C to MRP2. For 
E C G and E G C G , which have one more gallate group than EC and E G C respectively, 
only a little of efflux was observed, which suggested that the substitution of gallate 
group at 3-OH may greatly reduce the affinity of EGCG, E C G to MRP2. The 
findings suggest that the chemical structures at the B and C ring of tea catechins are 
critical for the recognition by MRP2. In comparison, substitution of gallate group at 
3-OH seems to have more effect than the presence of 5'-OH on the affinity of 
catechins to MRP2. Although the present study discovered the correlation between 
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chemical structure and efflux extent of catechins, further studies are needed to 
identify the specific binding sites on M R P 2 for tea catechins. 
2.5.5 Metabolism of GTC 
Several metabolites of G T C generated by Caco-2 cell were identified in the 
transport experiment. They were mainly sulfated and methylated metabolites. 
Methylation tends to take place at the 3'-OH or 4'-OH position of EC (Kuhle 
et al, 2000; Baba et al., 2001). Sulfate conjugate seems to be the major metabolites 
of EC in human (Vaidyanathan and Walle, 2002), while glucuronide was the major 
metabolite of EC in rat (Vaidyanathan and Walle, 2002; Kuhnle et al., 2000). Since 
Caco-2 cell is originated from human, types of the metabolites formed from the 
present study were consistent with the previous findings from human with no 
glucuronide observed. 
It has been reported that the metabolites of E G C are 4'-0-methyl EGC, 
methyl-EGC-O-sulfate and E G C sulfate conjugate in humans (Meng et al., 2001; Li 
et al., 2001). Consistently, the present study also found the same type of major 
metabolites of E G C i.e. E G C sulfate conjugate, methylated E G C and methylated 
E G C sulfate conjugate formed in the transport in Caco-2 cell model. 
Methylation of E G C G at 4'-OH and 4"-0H were previously reported 
(Okushio et al., 1999; Lu et al., 2003; Kida et al., 2000). The methyl group was also 
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found to conjugate at the 4"-0H of E C G (Kida et al., 2000). As to the type of 
metabolites of E G C G and ECG, our results are also consistent with previous finding. 
In the present study, identification of metabolites of the four G T C was 
carried out by LC/MS in selective ion monitoring (SIM) mode targeting at the 
deprotonated molecular ion of each metabolite. Except for EC sulfate conjugate, the 
mass spectra of the other metabolites were not available due to the low concentration 
of the metabolites in the samples. 
2.5.6 Relationship between metabolism and efflux transport of GTC 
The types of metabolites generated by Caco-2 cell found in the present study 
are consistent with the previous results obtained from both in vivo and in vitro 
studies (Harada et al., 1999; Okushio et al, 1999; Meng et al., 2001; Kuhnle et al., 
2000). What seemed to be interesting was that the metabolites preferentially 
appeared at the apical side regardless of the side of loading. This suggests that 
certain type of active transporter is involved in the selective localization of the 
metabolites formed in the Caco-2 cells. The presence of MK571 dramatically 
decreased the amount of metabolites of EC and E G C formed, suggesting that the 
metabolites were the substrates of MRP2. Previous studies on the relationship 
between A B C transporters (P-gp and M R P ) and Phase I and Phase II metabolic 
enzymes demonstrated that P-gp is capable to efflux Phase I metabolites and MRPl, 
2, 3 are capable of transporting Phase II metabolites such as glutathione conjugates, 
glucuronide conjugates, sulfate conjugates (Suzuki and Sugiyama, 2000). The 
metabolic enzymes and efflux transporters can cooperate to limit the entry of the 
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xenobiotics into the cells. This type of cooperation was also observed for EC and 
E G C in the current study. This indicated that the Caco-2 cells could eliminate EC 
and E G C by Phase II metabolic transformation followed with efflux transport as 
they did for the general xenobiotics 
Although the present study was performed with Caco-2 cells, which is 
originated from human colon, the M R P transporter and Phase II metabolic enzymes 
should as well be located in the intestine and even other secretion organs such as 
kidney and liver. This implies that the transport and metabolism in secretion 
direction happened in Caco-2 cell model may also take place in vivo such as in 
intestine, kidney and liver. But the extent of secretion transport and metabolism may 
vary because of the different extent of expression of the transporters and enzymes 
between Caco-2 cell and human intestine, kidney and liver. 
2.5.7 Bi-directional transport of GTC in different dosing formulations 
2.5.7.1 Absorption transport profile of different dosing formulations 
In the absorption transport, the Papp values of the four G T C in the four dosing 
formulations (individual pure compound, cocktail 1, cocktail 2 and green tea extract) 
are similar. Individual G T C has been found in m y earlier study that they were 
transported by paracellular pathway, which mainly depends on the sizes of the 
compounds. Therefore, dosing with cocktail 1, cocktail 2 and extract would result in 
the similar Papp value to those in individual pure compounds. These findings 
indicated that for the four G T C no additive effect was involved in the absorption 
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transport and the other co-occurring components in green tea extract provided no 
change on the absorption of the four studied green catechins. 
2.5.7.2 Secretion transport profile of different dosing formulations 
In the secretion transport, Papp of EC in cocktail 1 and cocktail 2 decreased 
slightly, when comparing to that of EC in the individual pure compound 
formulation. The reduced Papp may be due to the competition of EC with other G T C 
in the cocktail on MRP2. As demonstrated in the bi-directional transport study of 
individual GTC, E G C is not a strong substrate of M R P 2 with only medium extent of 
efflux, while E G C G and E C G are relatively poor substrates. Therefore, dosing with 
cocktail 1 and cocktail 2 conferred only a little inhibition on the efflux of EC in the 
present study. 
For secretion transport of EGC, the Papp values of E G C in cocktail 1 and 
cocktail 2 were enhanced significantly (P<0.05) comparing with that of E G C in 
individual pure compound formulation. This result did not agree with transporter 
competition theory. According to this theory, if two substrates shared the same 
transporter, the transport of one substrate should be reduced in the presence of the 
other substrate due to competition. Hence, efflux of E G C should decline in the 
presence of EC. However, the observation was just the opposite. Thus, another 
mechanism was proposed to explain the observation. 
Further studies on the transport profile of different formulations discovered 
that the metabolic competition of E G C took place when dosing with cocktail 1 and 
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cocktail 2. EC reduced the formation of E G C sulfate conjugate and methylated E G C 
sulfate conjugate. E G C G and E C G mainly decreased the generation of the 
methylated E G C sulfate conjugate. Besides the reduced amount of the metabolites of 
EGC, more E G C appeared in the receiver chambers. This finding suggests that 
metabolic competition should be a reasonable explanation for the greater extent of 
efflux of E G C when combined with other catechins. This increased Papp in secretion 
transport of E G C in two cocktails can be explained as the follow: In the secretion 
transport of individual pure EGC, E G C permeating into the Caco-2 cells is mainly 
transformed by Phase II metabolic enzymes into two metabolites. Then the parent 
compounds as well as the two metabolites are actively transported by M R P 2 into the 
apical side. When adding the cocktail in the secretion transport study, E G C in the 
Caco-2 cells competed with EC, E C G and E G C G present in the cocktail for the 
Phase II metabolic enzyme. The competition resulted in more unchanged E G C being 
left inside the Caco-2 cell, which can be secreted to the apical side and resulted in a 
much higher concentration of E G C (Figure 2.28). 
What is worth to be noticed in the secretion transport study of cocktail 1 is 
that the effects of efflux transporter competition and the metabolic competition on 
the secretion rate of G T C can not be completely separated from each other. During 
secretion transport of cocktail 1, transporter competition tents to decrease the Papp 
value of each GTC, while metabolic competition will result in increased Papp values 
of each GTC. In the case of EC during secretion transport of cocktail 1, transporter 
competition should be regarded as the predominant factor resulting in a decreased 
Papp value, while the possible involvement of metabolic competition could not be 
excluded. Similarly, the increased secretion rate of E G C in cocktail 1 during its 
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secretion transport was caused mainly by the metabolic competition of E G C with 
other GTC, and the effect of transporter competition may be the minor factor in this 
case. 
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In Caco-2 cell model, the four GTC are absorbed by paracellular pathway. 
Structure related efflux mediated by MRP2 is involved in the secretion transport of 
the four GTC. During secretion transport, methylation and sulfation take place. 
Comparing the bi-directional transport profile of different dosing formulations of 
GTC, no additive effect among the GTC is involved in their absorption transport. 
Matrix in the green tea extract shows no effect on the absorption of the four GTC. 
Metabolic competition is likely to be involved in the secretion transport of the 




Transport mechanism of hawthorn flavonoids 
3.1 Introduction 
Hawthorn {Crataegus) has been used as traditional Chinese medicine for a 
long time (Gao et al., 1994). In China, the hawthorn fruit was used to improve 
digestion and relieve food stasis (Ding et al., 1990; Chen et al., 1995). In Europe, the 
fruit, leaf and flower of hawthorn are used for astringent, diuretic, and 
cardiovascular disease (Leung et al., 1996; Cupp et al., 2000). 
The chemical components of hawthorn are composed of sterols, triterpene 
acids, flavonoids, oligomeric proanthocynanidins, organic acids and cardioactive 
amines etc. (Chang et al., 2002a). The pharmacological effects were believed to be 
mainly due to the hawthorn flavonoids (HF), which possess a number of beneficial 
effects such as inotonic (Awang and Fugh-Berman, 2002), antiarrhythmic (Mueller 
et al., 1996), hypolipidemic (Zhang et al., 2002), antihypertensive (Chen et al., 
1998) and antioxidative activities (Zhang et al., 2001). 
HF are mainly composed of hyperoside, quercetin, quercitrin, isoquercitrin, 
rutin, vitexin, isovitexin, epicatechin (Chang et al., 2002a). Among them, EC, IQ, 
and HP (Figure 1.3) are the major active flavonoids in hawthorn fruit extract with 




Although the pharmacological effects of HF have been substantially 
reported, their in vivo pharmacokinetics and uptake mechanism have not been 
clearly defined. The in vivo data of EC were mainly generated from the studies after 
coadministration with other green tea catechins (Chen et a l , 1997; Chow et a l , 
2001). The absorption of HP is uncertain from the published literature. The 
absorption mechanism reported on IQ and its analog, quercitin-4‘-glucoside, is 
contradictory (Sesink et al., 2003). The absorption of these glucosides has been 
generally proposed to involve hydrolysis of the glucosides to quercetin aglycone in 
the small intestine before entry into systemic circulation (Walle et al., 2000). 
However, the active transport by SGLTl has also been suggested for the intestinal 
absorption of glucosides. (Hollman et al., 1995). 
The present study focuses on studying the transport mechanism of the three 
major active HF, (EC, IQ and HP) using Caco-2 cell model. In addition, transport 
profile of individual pure compound, mixture of pure compounds and extract 
formulations are studied and compared. 
3.2 Materials 
3.2.1 Chemicals 
IQ and HP were purchased from Carl Roth, Germany. Epicatechin, 
verapamil, rutin and phosphate buffer tables were from Sigma Chemical Co., USA. 
MK 571 was supplied by Biomol Research Laboratories Inc., USA. The hawthorn 
extract was kindly provided by Dr. Chang (School of Pharmacy, The Chinese 
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University of Hong Kong). HPLC grade methanol and acetonitrile were from 
Lab scan Asia Co. Ltd., Thailand. Other chemical reagents used were at least of 
analytical grade. 
3.2.2 Materials for cell culture 
DMEM, FBS, 0.05% Trypsin-EDTA, Penicillin-Streptomycin, and non-
essential amino acids were obtained from GibcoBRL, Life & Technologies, USA. 
Collagen type I, USA, sodium pyruvate was purchased from Sigma Chemical Co., 
USA. Caco-2 cells were obtained from the ATCC. Six-well transwell® plates (0.4|im 
pore size, 4.71 cm , polycarbonate filter) were purchased from Coming Costar Co., 
NY, USA. 
3.2.3 Instruments 
The HPLC system used was composed of Waters 2690 separation module, 
Waters 996 photodiode array (PDA) detector and Waters 464 pulsed electrochemical 
detector (ECD). BDS reversed phase column (4.6mm I.D. x 250 mm, 5|Lim, Thermo 
Hypersil) equipped with Hypersil BDS CI8 guard column (Alltech) was employed. 
HPLC/MS was performed on API 2000 Triple Quadmpole LC/MS/MS 
spectrometer. Two Perkin-Elmer PE-200 series micro-pumps and auto-sampler 




3.3.1 Analytical methods for HF 
3.3.1.1 Analytical methods of individual pure compound of HF 
3.3.1.1.1 HPLC analysis of HP and IQ 
A 150 |il sample was acidified with 10 jil of 1% ascorbic acid solution 
containing 0.28% H3PO4, then spiked with 10 \il of 5 |ig/ml rutin (quercetin-3-
rutinoside) as an internal standard. Gradient elution was employed for separation of 
the two compounds. In detail, the gradient was started with 20 % acetonitrile and 80 
0/0 25mM phosphate buffer (pH2.5) and changed linearly to 25% acetonitrile and 
75% phosphate buffer in 10 minutes. Subsequently, the mobile phase was changed 
back to 20 % acetonitrile and 80% phosphate buffer in the next 5 minutes. The flow 
rate was set at 1 ml/min. Samples were analysed at 356 nm for both HP and IQ. 
3.3.1.1.2 HPLC analysis of EC 
The concentration of EC was determined by HPLC as described in Chapter 
two (Section 2.3.1.2.1). 
3.3.1.2 Preparation of calibration curves for individual pure HF 
Primary stock solutions of each HF were prepared by dissolving accurately 
weighted quantities of the standard compound in methanol to reach a concentration 
of 2 mg/ml. The 10 |ig/ml working stock solution of each HF was obtained by 
dilution with aqueous solution (pH=2.5) containing 0.125% ascorbic acid. The stock 
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solutions were then stored under —80�C. The calibration curve of each HF was 
prepared by serial dilution of working stock solution with 0.125% ascorbic acid 
aqueous solution (pH2.5) to reach 1000 ng/ml, 500 ng/ml, 200 ng/ml, 100 ng/ml, 50 
ng/ml, and 25 ng/ml, respectively. 
3.3.1.3 HPLC/MS analysis of three HF in mixture 
A 150 |il sample was acidified with 10 |LI1 1% ascorbic acid solution 
containing 0.28% H3PO4. Then it was spiked with 10 id of 10 |ig/ml naringin as an 
internal standard. A BDS CI8 reversed phase column (4.6mm I.D. x 250 mm, 5jim, 
Thermo Hyersil) was used for separation. The gradient began with 10% acetonitrile 
and 90% water with 0.04% formic acid (pH3.0) and was changed linearly to 22% 
acetonitrile and 78% water in 20 minutes, then followed by changing linearly to 
30% acetonitrile and 70% water in 2 minutes. Afterwards, the gradient was changed 
back to 10% methanol and 90 % water in the next 4 minutes. A flow rate of 1 
ml/min was selected. Twenty percent of eluent was introduced into mass 
spectrometer for analysis and the other 80 % was splitted off. 
Negative mode was set for analysis. The other mass spectrometer working 
parameters were as follows: orifice voltage, -82V; ring voltage, -230V; nebulization 
gas, 23psi; auxiliary gas, 40psi; nebulizer temperature, 400 
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3.3.1.4 Preparation of the calibration curves of three HF in mixture 
Primary stock solutions of HF were prepared by dissolving accurately 
weighted quantities of each standard compound in methanol to reach 2 mg/ml. The 
10 |ig/ml working stock solution of mixture of the three HF was obtained by dilution 
with aqueous solution (pH=2.5) containing 0.125% ascorbic acid. The stock 
solutions were stored under -80°C. The calibration curve was prepared by serial 
dilution with 0.125% ascorbic acid aqueous solution (pH2.5) from working stock 
solution to reach 500 ng/ml, 200 ng/ml, 100 ng/ml, 50 ng/ml, 20 ng/ml, and 10 
ng/ml, respectively. 
3.3.1.5 Validation of HPLC methods 
Validation of HPLC method was conducted by determining the intra-day, 
inter-day accuracy and precision at high, middle and low concentration levels. The 
precision of the assay was defined as the RSD and the accuracy was the percentage 
difference of the determined concentration from nominal value, % Difference 
=(determined - nominal) / nominal] x 100. The linearity of calibration curve was 
examined as well. 
3.3.2 Analytical methods for identification of metabolites with HPLC/MS 
For EC, ODS reversed phase column (4.6mm LD. x 250 mm, 4.5|Lim, 
Beckman) with gradient at a flow rate of 1 ml/min was selected. The gradient began 
with 10% of acetonitrile and 90% of water with 0.04% of formic acid, and was 
changed to 30% of acetonitrile and 70% of water in 20 min. Then it was changed 
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back to 10% of acetonitrile and 90% of water in 2 min. Twenty percent of eluent 
was introduced into mass spectrometer and the other 80 % was splitted off. 
For analysis of IQ and HP, BDS reversed phase column (4.6mm I.D. x 250 
mm, 4.5jim, Thermo Hypersil) was eluted with gradient at a flow rate of 1 ml/min. 
The gradient was changed from 20% of acetonitrile and 80% water with 0.04% 
formic acid to 25% acetonitrile and 75% water in 10 min, followed by being 
changed back to 20% acetonitrile and 80% water in 5 min. Eighty percent of the 
eluent was splitted out so that only 20% of the eluent entered the mass spectrometer. 
Negative mode was set for analysis. The other working mass spectrometer 
parameters were as follows: orifice voltage, -82V; ring voltage, -230V; nebulization 
gas, 23psi; auxiliary gas, 40psi; nebulizer temperature, 400 Deprotonated 
molecular ions of the possible metabolites of EC including methylated, sulfate 
conjugate, glucuronidated conjugate, methylated sulfate conjugate, methylated 
glucuronidated conjugate metabolites as well as possible methylated metabolites of 
HP and IQ, were monitored. 
3.3.3 Cell culture 




3.3.4 Cytotoxicity test 
The procedures were similar to what has been described in Section 2.4.4.4, 
except for that the hawthorn extract dissolved in PBS+ (pH 6.8) at concentrations of 
1.5, 0.75, 0.38, 0.19, 0.094, 0.047, 0.023 mg/ml, respectively, were examined. The 
cytotoxicity of the extract was calculated as the percentage of the absorbance 
relative to control. 
3.3.5 Transport studies of HF using Caco-2 monolayer model 
3.3.5.1 Bi-directional transport experiment 
Transwell® inserts with Caco-2 grown on it were rinsed twice with PBS+ 
transport buffer and equilibrated at 3 7 � C with PBS+ buffer for 15 min before the 
transport experiment. In the absorption transport study, 1.5 ml of compound solution 
in PBS+ at appropriate concentration was loaded at the apical (AP) side (donor 
chamber), and 2.6 ml of blank PBS+ was placed at the basolateral (BL) side 
(receiver chamber). In the secretion transport, 2.6 ml of testing solution was placed 
at BL side (donor chamber) and 1.5 ml of blank PBS+ at the AP side (receiver 
chamber). Aliquots of 0.5 ml samples were taken from the receiver chamber at 
different time intervals after loading (30, 60, 90, 120, 180 min). After each 
sampling, an equal volume of blank PBS+ was replaced to the receiver chamber to 
maintain a constant volume. 
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3.3.5.2 Preparation of loading solutions in different dosing formulations of HF 
for Caco-2 cell model 
3.3.5.2.1 Preparation of individual pure HF solutions 
Individual pure HF solutions were prepared by dissolving each HF in the 
PBS+ transport buffer (pH6.8) to reach 50 ^iM. 
3.3.5.2.2 Preparation of cocktail 1 solution 
Cocktail 1 solution was prepared by mixing all three pure HF solutions in the 
PBS+ transport buffer (pH 6.8) to make a 50 ]iM solution for each compound. 
3.3.5.2.3 Preparation of hawthorn extract solution 
Hawthorn extract solution was prepared by dissolving hawthorn extract 
powder in the PBS+ transport buffer (pH 6.8) to reach a concentration of 1.1 mg/ml. 
The final solution contained 23.3 昭/ml (50|LIM) of IQ, 32.5 lug/ml (70 |aM) of HP, 
175 |ag/ml (603 _ of EC. 
3.3.5.2.4 Preparation of cocktail 2 solution 
Cocktail 2 solution was prepared by dissolving three pure HF in the PBS+ 
transport buffer pH 6.8 to make each flavonoid reach the same molar concentration 
as that in the hawthorn extract solution. 
The concentration of each HF in PBS+ was summarized in Table 3.1. 
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Table 3.1 Loading solutions of different dosing formulations of HF to Caco-2 
cell model 
Individual Cocktail 1 Cocktail 2 Extract 
pure 
compounds 
Concentration in PBS+ (pH6.8) (|iM) 
50 50 m m 
HP 50 50 70 70 
IQ 50 50 50 50 
3.3.5.3 Sample treatment 
In order to ensure the stability of the samples during the analysis period in 
the auto-sampler, samples obtained from Caco-2 model were acidified prior to 
HPLC analysis. 
Samples from the transport study of EC were acidified with 1% ascorbic acid 
and 0.28% H3PO4, so that a sample to ascorbic acid solution ratio was 150:25 (v/v). 
Samples from the transport studies of pure IQ, HP, cocktail and extract formulations 
were also acidified with acid solution mentioned above so as to achieve a sample to 
acid solution ratio of 150:10 (v/v). 
3.3.5.4 Further study of the transport mechanism of HF 
3.3.5.4.1 Inhibition transport of EC, IQ, and HP 
In order to identify the possible efflux transporters involved in the absorption 
process, the bi-directional transport experiments were conducted in the presence of 
MK571, a typical MRP2 inhibitor (Vaidyanathan and Walle, 2001; Walgren et al., 
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2000). A 50 fiM of MK571 was preloaded at the apical side for 20 min. The bi-
directional transport study was then performed in the presence of 50 |iM of MK571 
at the donor chamber. 
To evaluate the contribution of P-gp, bi-directional transport experiment was 
also performed in the presence of verapamil, a typical P-gp inhibitor. A 100 |iM of 
verapamil was preloaded at both sides of the chambers for 20 min. The bi-
directional transport studies were then conducted in the presence of 100 |iM of 
verapamil at both sides of chambers. 
3.3.5.4.2 Transport mechanisms of the metabolites of EC, HP, IQ 
Samples were taken from the receiver chambers at the end of the secretion 
transport experiment of EC, HP, IQ in the presence or absence of various inhibitors 
(verapamil and MK571) and were analyzed with HPLC/ECD, HPLC/ UV and 
HPLC/MS. The chromato grams of the samples were compared to examine the effect 
of transport inhibitors on the transport of metabolites of EC and EGC. 
3.3.6 Calculation 
The apparent permeability coefficient (Papp) was calculated according to the 
following equation: Papp = [(dC/dt xV)]/(A x C), where "dC/dt" (ng/ml/sec) is the 
change of the drug concentration in the receiver chamber over time, "V" (ml) is the 
volume of the solution in the receiver chamber. In this case, "V" is equal to 2.6 ml 
for the transport study from apical side to basalateral side; “V” is equal to 1.5 ml for 
transport study from basalateral side to apical side; "A" (cm^) represents the 
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membrane surface area of 4.7 cm ； “ C , (ng/ml) is the initial concentration in the 
donor chamber. Samples were taken at 30, 60, 90, 120, 150, 180 min. 
Recovery was calculated as follows: 
Recovery (%)= 
The final amount of the parent compound found in both donor and receiver chamber IQQy 
The initial amount of the parent compound loaded in the donor chamber 
3.3.7 Data analysis 
Reported values are presented as mean 士 SD (n=3). Data were tested by 
Student's t test. For all tests, a level of P<0.05 was considered significant. 
Comparison of the transport profile was conducted between individual pure 
HF (50 |iM) and cocktail 1 (the mixture formulation of three HF at the same molar 
concentration of 50 |iM) in order to discover the potential additive effect among the 
three HF on the transport process. Comparison of the transport profile between 
cocktail 2 and hawthorn extract were also studied to determine the possible effect of 




3.4.1 Validation of the HPLC methods 
The calibration curves of the three HF were linear over the studied 
concentration ranges. The intra-day, inter-day precision and accuracy of the three 
HF at high, middle, low concentrations were within 10% (Table 3.2, Table 3.3). 
These results indicated that the developed HPLC methods were suitable for the 
sample analysis. 
3.4.2 Cytotoxicity test 
As shown in Figure 3.1, no significant reduction of the percentage of 
absorbance was observed in comparison with the negative control. This result 
indicates that there is no cytotoxicity of the hawthorn extract at a loading 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.4.3 Transport study of HF 
3.4.3.1 Bi-directional transport of individual pure HF 
Significant efflux was observed with all three HF. The absorption transport 
of the three HF were all fairly poor with Papp values of 0.99±0.06xl0-7cm/sec, 
1.43±0.23x10-7 cm/sec, 0.61±0.17xl0-7 cm/sec, for EC, IQ, HP, respectively. 
However, the secretion transport of the three HF was much faster than their 
7 7 
absorption transport, with Papp values of 23.37±0.18x10" cm/sec, 23.86±1.33 xlO' 
cm/sec, 19.19+1.66x10"^ cm/sec for EC, IQ, HP, respectively (Figure 3.2). The 
recovery values of the studied HF were 90.6±2.5%, 83.4±13.2o/o and 96.3±5.5o/o for 
HP, IQ and EC respectively. 
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3.4.3.2 Bi-directional transport of the HF in different formulations 
3.4.3.2.1 Absorption transport of different formulations of HF 
Comparing absorption profile of the three HF as pure individual compound 
form and that as cocktail 1, the Papp values of EC, HP and IQ in cocktail 1 were 
slightly higher (Figure 3.3, 3.4). However, the increase of the Papp was marginal and 
the Papp values of three HF for the absorption transport were within the range of 
paracellular markers. These results indicated that the three HF have only marginally 
additive effect on the absorption of each other. When comparing the absorption 
profiles of three HF in cocktail 2 and extract, there is no significant difference 
between the Papp values of EC, HP and IQ in the two formulations. This indicates 
that the matrix component in the extract has no effect on the absorption of the three 
HF. 
3.4.3.2.2 Secretion transport of different dosing forms 
As indicated in Figure 3.3, 3.4, 3.5, transporter competition among the three 
HF might be involved in their secretion transport. Comparing with the secretion 
transport of each HF in individual pure form, their secretion transport efficiency in 
cocktail 1 was significantly decreased with Papp values of 11.09±1.57x10'^ cm/sec, 
5.17±0.23x10-7 cm/sec and 15.19±1.72xl0"^ cm/sec for EC, HP and IQ respectively. 
The rate of secretion transport of the three HF in cocktail 2 was reduced further with 
Papp values of EC (4.69±0.49xl0"'^ cm/sec), HP (3.58+0.25x10"'^ cm/sec) and IQ 
(7.74±0.31X10-7 cm/sec) within the range of paracellular markers. 
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In the secretion transport study of extract, loading the hawthorn extract to the 
2 
basalateral side led to substantial dropping of TEER value (from about 1300 Q- cm 
to 600 Q- cm^) after only half an hour, indicating damage of integrity of the 
monolayer. However, such damage was not observed in the absorption transport of 
the extract after loading the same concentration of extract to the apical side of the 
chamber. These observations indicate that matrix in the hawthorn extract may have 
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Figure 3.3 Bi-directional transport of EC in different dosing formulations 
(n=3). #: Papp value (BL to AP) of EC in individual form is 
significantly different from that in cocktail 1 (BL to AP) (P<0.05). 
N. A.: not available 
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Figure 3.4 Bi-directional transport of HP in different dosing formulations (n=3). 
*: Papp value (AP to BL) of HP in individual form is significantly 
different from that in cocktail 1 (AP to BL). #: Papp value (BL to AP) 
of HP in individual form is significantly different from that in cocktail 
1 (BL to AP) (P<0.05). N. A.: not available 
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Figure 3.5 Bi-directional transport of IQ in different dosing formulations (n=3). 
*: Papp value (AP to BL) of IQ in individual form is significantly different 
from that in cocktail 1 (AP to BL). #: P^p value (BL to AP) of IQ in 
individual form is significantly different from that in cocktail 1 (BL to AP) 
(P<0.05). N. A.: not available. 
3.4.3.3 Identification of metabolites of each HF formed during their transport 
in Caco-2 model 
EC 
In the secretion transport experiment, several metabolites (Ml , M2, M3) 
(Figure 3.6 A) of EC were detected by HPLC with ECD in the receiver chamber. 
However, none of the above metabolites was found in the receiver chamber for the 
absorption transport experiment (Figure 3.6 B). LC/MS analysis with selective ion 
monitoring (SIM) in negative molecular ion mode further confirmed that the 
metabolites were EC sulfate conjugate (m/z, 303), methylated EC (m/z, 369), and 
methylated sulfate conjugate (m/z, 383) (Figure 3.7 A). The samples taken from the 
receiver chamber in absorption transport were also applied to HPLC/MS. The results 
were consistent with those observed with HPLC/ECD detector i.e. marginal amount 
of metabolites occurred in receiver chamber during absorption transport experiment 
(Figure 3.7 B). Moreover, the metabolites of EC were observed in the donor 
chamber of both absorption and secretion transport studies (Appendix I). 
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Figure. 3.6 HPLC/ECD chromato grams of the samples taken from receiver chambers at 
the end of the transport experiment of EC. (A) Basalateral loading and apical 
sampling. (B) Apical loading and basalateral sampling. (C) Basalateral 
loading and apical sampling in the presence of verapamil (D) Basalateral 
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Figure 3.7 LC/MS chromato grams of the samples taken from receiver chambers at the 
end of the transport experiment of EC. (A) Basalateral loading and apical 
sampling. (B) Apical loading and basalateral sampling. EC: epicatechin. 
EC-sulfate: epicatechin sulfate conjugate. Me-EC: methylated epicatechin. 
Me-EC-sulfate: methylated epicatechin sulfate conjugate. 
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10 and HP 
In the absorption transport study, no metabolite of HP and IQ was found in 
the receiver chamber with HPLC/UV detection (Figure 3.8A, 3.9A). 
In the secretion transport study, two metabolites were discovered for both HP 
and IQ (Figure 3.8B, 3.9B). The UV spectra of metabolites of HP and IQ were 
almost identical to their parent compounds (Figure 3.10). The metabolites of IQ and 
HP were further analyzed with HPLC/MS and HPLC/MS/MS. HPLC/MS with 
negative mode, targeting at the deprotonated molecular ion of the metabolites. The 
two metabolites of both HP and IQ were found to be the methylated HP and 
methylated IQ (m/z, 477) (Figure 3.11, Figure 3.12). HPLC/MS/MS in multiple 
reaction monitoring (MRM) mode was used, monitoring the transition of the 
deprotonated molecular ions of methylated HP and methylated IQ (m/z, 477) to their 
major product ion of methylated quercetin (m/z, 314). LC/MS/MS further confirmed 
the existence of methylated HP and methylated IQ in the receiver chamber (Figure 
3.13, 3.14). The metabolites of HP and IQ were also found in the donor chambers of 
both absorption and secretion transport studies (Appendix V, VI). 
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Figure 3.8 HPLC/UV chromatograms of the samples taken from receiver chambers at 
the end of the transport experiment of HP. (A) Apical loading and 
basalateral sampling. (B) Basalateral loading and apical sampling. (C) 
Basalateral loading and apical sampling in the presence of verapamil. (D) 
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Figure 3.9 HPLC/UV chromatograms of the samples taken from receiver 
chambers at the end of the transport experiment of IQ. (A) Apical 
loading and basalateral sampling. (B) Basalateral loading and apical 
sampling. (C) Basalateral loading and apical sampling in the presence 
of verapamil. (D) Basalateral loading and apical sampling in the 
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Figure 3.11 LC/MS chromatograms of the samples taken from receiver chambers at 
the end of the transport experiment of HP. (A) Basalateral loading and 
apical sampling. (B) Apical loading and basalateral sampling. HP: 
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Figure 3.12 LC/MS chromato grams of the samples taken from receiver chambers 
at the end of the transport experiment of IQ. (A) Basalateral loading 
and apical sampling. (B) Apical loading and basalateral sampling. IQ: 









\ I 双 ； \ I i I 1虹i i 




HCC^  I 
W f I 
纟丨I i 
2CO- I > .i. I 
〜 0 71 2.13 4.03 +.艾 5.19 C.OO (l.Dt 7.4Q S.12 ‘ ‘ IMS  丨 义 ‘ “ ^ ‘ ‘ 1U “ “ 、 ‘ • 
Figure 3.13 LC/MS/MS chromatogram (MRM m/z 477 -> 314) of the samples 
taken from receiver chambers at the end of the secretion transport 
experiment of HP. 
“" i 丨 10 丨?s 
CEO i ： ；; 
i 
H m/z 477 —314 Me-IQ i 
I 1 i • 
奶:H i 
《 0 - ： 
备.3ro-| i 
.-I； ； i \ ： j 
^ j ； i 
- so - 丨 
2C0- 丨 i i 
i i i ： ！0:2? 丨 i 
j I： ： 
1C01 ； I i! =• i i : i i 
C.口 （、[躲 1.S1 2.D3 : T sec C37 3 "0 ^^ ； 口 12.G5 _。 
^ _ > ‘ , ^ . . ‘ . . , 
• 2 ：4. s 7 e V-l 11 ： I  
Tinhe.rnlii -J 1 
Figure 3.14 LC/MS/MS chromatogram (MRM m/z 477 -> 314) of the samples 
taken from receiver chambers at the end of the secretion transport 
experiment of IQ. 
135 
Chapter Three 
3.4.4 Further study on the transport mechanism 
3.4.4.1 Inhibition transport of EC, HP, IQ 
As shown in Figure 3.15, 3.16, 3.17, 50 jiM of MK571，effectively inhibited 
the efflux transport of EC, IQ and HP. The Papp values from absorption and secretion 
studies are similar and comparable to that of the paracellular markers. These data 
suggested that the carrier-mediated pathway in secretion transport was inhibited 
significantly by M K 5 7 1 . However, 1 0 0 |LIM verapamil only conferred a slight 
inhibition on the efflux of HF (Figure 3.15, 3.16，3.17). In view of the potent 
inhibition by MK 571, these hawthorn flavonoids (EC, IQ and HP) appear to be a 
much stronger substrate of MPR2 than P-gp. 
3.4.4.2 Transport mechanism of metabolites of HF 
In the presence of MK571, the formation of methylated IQ and methylated 
HP as well as all the metabolites of EC (EC sulfate conjugate, methylated EC and 
methylated EC sulfate conjugate) were substantially reduced (Figure 3.6 D, 3.8 D, 
3.9 D). Addition of verapamil had only a little effect on the transport of metabolites, 
indicating that the transport of the metabolites is mediated by MRP2 more than P-gp 
(Figure 3.6 C, 3.8 C, 3.9 C). 
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Figure 3.15 Bi-directional transport of EC in the presence and absence of various 
inhibitors (n=3). *: Papp values (BL to AP) of EC in the presence of 
verapamil and MK 571 are significantly different from that (BL to AP) in 
the absence of any inhibitors (P<0.05). 
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Figure 3.16 Bi-directional transport of HP in the presence and absence of various 
inhibitors (n=3). Papp values (BL to AP) of HP in the presence of 
verapamil and MK 571 are significantly different from that (BL to AP) in 
the absence of any inhibitors (P<0.05). 
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Figure 3.17 Bi-directional transport of IQ in the presence and absence of various 
inhibitors (n=3). *: Papp values (BL to AP) of IQ in the presence of 
verapamil and MK 571 are significantly different from that (BL to 
AP) in the absence of any inhibitors (P<0.05). 
3.4.4.3 Transport profiles of HF metabolites upon the loading of different 
dosing formulations of HF 
In the secretion transport of the HF in cocktail 1 and cocktail 2, transporter 
competition was observed for EC, HP and IQ with significantly reduced Papp of each 
compound. Concurrently, the amount of metabolites actively secreted by MRP2 to 
the receiver chamber was also reduced (Figure 3.18, 3.19). The reduced amount of 
the metabolites in the receiver chamber might be due to the transporter competition 
between the metabolites and their parent compounds. However, the metabolic 
competition among the three HF may also be possible since the three HF share a 
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EC (n=3). EC-sul: EC sulfate conjugate. Me-EC: methylated EC. *: The 
amount of EC-sul formed at apical side during secretion transport of cocktail 1 
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J 0 H P / I Q 丨 
3 j — ^ l I I C o c k t a i l 1 
w • C o c k t a i l 2 1 
: 2 5 」 j 
(1) i • vJ 0 J 
1 2 — [ 忽 ^ 1 
！ 1.5-— 1 — — I 0) I ^ L . . J 
•i 1 — " T i 
0) 
a. 氺 I I 0.5 — I 
0 B i N . D . L J L ^ I 
Me-HP Me-IQ 
Figure 3. 19 Effect of different dosing formulations on the formation of the metabolites of 
IQ and HP (n=3). Me-HP: methylated HP, Me-IQ: methylated IQ. The 
amount of Me-HP formed at apical side during secretion transport of cocktail 
1 and cocktail 2 is significantly different from that during secretion transport 
of individual form (P<0.05). #: The amount of Me-IQ formed at apical side 
during secretion transport of cocktail 1 and cocktail 2 is significantly 
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3.5 Discussion 
3.5.1 Bi-directional transport of each HF 
In the absorption transport study, Papp values of the three HF were similar 
and comparable to those of the paracelluar markers, indicating that the absorption 
transport of EC, IQ and HP is mainly via paracellular pathway. A previous study 
proposed that the failure to demonstrate active carrier-mediated transport (such as 
SGLTl) of quercetin glucoside absorption transport in Caco-2 cell model was due to 
an efficient efflux of quercetin glucoside by MRP2 (Ader et al., 2001). However, the 
present study showed that after inhibition of the efflux of IQ and HP (mediated by 
MRP2) by MK571, the transport rates of absorption and secretion were similar and 
comparable to those of paracellular markers. Thus, it was suggested that there 
should be no active transport involved in the absorption process and the failure to 
demonstrate active absorption in the Caco-2 cell model might not be due to the 
effective efflux mediated by MRP2. 
In the secretion transport study, the three HF could be transported via both 
paracellular pathway and transcellular carrier-mediated pathway mediated by MRP2. 
As carrier-mediated transport is much more efficient than paracellular transport, 
three HF may mainly be actively secreted by MRP2 via transcellular pathway with 
Papp values much greater than those via paracellular transport. As active transcellular 
transport involves effective passing of the three HF through the cells, metabolites of 
the three HF were formed during this process and actively secreted to the apical side 
by MRP2. In the presence of MK571, the carrier-mediated transport pathway was 
140 
Chapter Three 
inhibited and the transport of EC, IQ and HP had to depend on passive diffusion via 
paracellular pathway. Thus, its Papp values resulted in the range of paracellular 
markers. 
3.5.2 Bi-directional transport of HF in different formulations 
Comparing the Papp during the secretion transport of the three HF using the 
individual pure form and cocktail 1, the decreased Papp was observed with cocktail 1. 
This indicates that competition on MRP2 among the three substrates took place and 
saturation of MRP2 might be reached as a result of increasing number of substrates 
with similar concentration existed in cocktail 1. In cocktail 2, the greatly increased 
loading concentration of EC (603 |LtM) may lead to the further saturation of MRP2, 
which resulted in a further reduced Papp. The extent of saturation of MRP2 might 
also lead to reduction on the efficiency of MRP2 on secreting the metabolites of the 
three HF. 
Although the loading concentrations of each HF in the two cocktail 
formulations were not less than that in the individual compound formulation, lower 
amount of metabolites was found at the apical side in the secretion transport. The 
reduced amount of the metabolites might be due to both transporter competition and 
metabolism competition. Theoretically, only evidence to support the existence of 
metabolic competition in Caco-2 cell among the three HF during secretion transport 
was the observation of increased Papp values of their parent compounds. If metabolic 
competition among EC, IQ and HP takes place, more parent compounds would 
escape from Phase II metabolism and less metabolites would be generated. This 
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would result in more parent compounds being actively secreted to the apical side. 
Therefore, the Papp values of parent compounds would be increased when cocktail 1 
or cocktail 2 is used. However, the observed Papp values of all three HF were 
reduced substantially when using cocktail 1 or cocktail 2. Thus, there is no evidence 
to support the existence of metabolic competition among the HF. On the other hand, 
same type of metabolites (methylated EC, methylated IQ and methylated HP) was 
formed during the secretion transport study. Metabolic competition among EC, HP 
and IQ could not be excluded. Further in vitro incubation study with human 
intestinal microsome could be conducted to verify whether metabolic competition 
exists or not. 
3.6 Conclusion 
In the Caco-2 cell model, paracellular transport is involved for the three HF 
in their absorption transport, while active transport mediated by MRP2 is involved 
in their secretion transport. During secretion transport, methylated and sulfated 
metabolites are formed from EC and methylated metabolites from IQ and HP. Little 
difference in the absorption transport of three HF is found when applied with 
different formulations. However, transporter competition occurs during secretion 
transport of the three HF in the mixture formulations and has resulted in reduced 




Limitations of the current study 
The present study investigated the transport mechanism of the four green tea 
catechins and the three hawthorn flavonoids using Caco-2 cell monolayer model In 
addition, the metabolites of the flavonoids formed during their transport process 
were also identified and their transport mechanism was studied. However, limitation 
of the study should be taken into the consideration when trying to extrapolate the 
present results to the in vivo situation. 
Firstly, the absorption of the selected flavonoids in Caco-2 cell model relies 
on the paracellular transport pathway, which is mainly related to the molecular size 
of the compounds. However, the cellular junction between the Caco-2 cells may be 
too "tight" to distinguish the molecular size difference of the drugs that are absorbed 
paracellularly. Hence, the size and molecular weight discrepancy between non-
gallated and gallated catechins could not be completely reflected on their 
permeability obtained from Caco-2 cell model. Further studies using the in situ 
intestinal perfusion model, which is most reflective of the pore size of the tight 
junction of the intestinal epithelium, should be able to provide a much closer picture 
of Papp values as that in the in vivo situation. 
Secondly, 50 [iM was chosen as the loading concentration for each studied 
flavonoid in forms of individual pure compound, cocktail 1 as well as the lowest 
concentration of flavonoids in cocktail 2 and extract. The concentration selection is 
based on the compromise between the detection limit of the analytical method and 
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the concentration to cause cytotoxicity to the Caco-2 cells. Therefore, the 
concentrations employed in the study may not completely reflect those in the in vivo 
situation. 
Thirdly, extensive efflux of EC, IQ and HP (mediated by MRP2) was found 
during their secretion transport study. These results imply that MRP2 plays an 
important role in the elimination of EC, IQ, HP at the small intestine or at kidney or 
liver where the expression of MRP2 is found (Cole et al., 1992). However, the 
contribution of efflux of EC, IQ and HP in intestine may still be uncertain, since the 
elimination in vivo can be lot more complicated than in vitro. 
Fourthly, although Caco-2 cells are originally from human, they are cancer 
cells. Hence, in terms of the expression of transporters, they may differ from the 
normal intestinal epithelium cells (Sun et al., 2002). In the present study, no active 
absorption of the selected flavonoids is observed. However, these results do not 
necessarily mean that no active absorption is present in vivo. 
Finally, the identification of metabolites was mainly based on the LC/MS 
analysis in selective ion monitoring (SIM) mode and LC/MS/MS in multiple 
reaction monitoring (MRM) mode. Except for EC sulfate conjugate, the mass 
spectra of the other metabolites formed during transport studies are not available due 
to their low concentrations in the samples. It would be more convincing to provide 
mass spectra of the metabolites and to perform NMR for identification of the 
structure of each metabolite. Therefore, further studies should be performed to give 
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stronger evidence for the type and quantification of the amount of the metabolites 





The present study was designed to characterize the intestinal absorption 
mechanism of green tea catechins and hawthorn flavonoids using a Caco-2 cell 
monolayer model. 
The bi-directional transport study of green tea catechins was performed. In 
absorption transport, four green tea catechins were absorbed most likely via 
paracellular pathway. In the secretion transport, structure related efflux mediated by 
MRP 2 was observed. The extent of efflux followed the descending order: EC > 
EGC > ECG > EGCG. Formation of the methylated and sulfated metabolites was 
observed in the secretion transport. The bi-directional transport profile of the four 
green tea catechins in four formulations as individual pure compounds, cocktail 1 
(the mixture of pure compounds with the same molar concentration of 50 jiM), 
cocktail 2 (the mixture of pure compounds with same molar concentration as that in 
the extract solution) and plant extract were compared. In absorption transport, 
similar transport profile of the four green tea catechins was observed among 
different formulations. Metabolic competition might exist in the secretion transport 
of the four green tea catechins when the mixture formulations of GTC were used. 
The bi-directional transport of the three hawthorn flavonoids was also 
studied. In absorption transport, three hawthorn flavonoids were transported via 
paracellular pathway in Caco-2 cell model. In secretion transport, efflux mediated by 
MRP2 was discovered for all three hawthorn flavonoids. In addition, methylated, 
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sulfated EC as well as methylated HP and IQ were found during the secretion 
transport of EC, HP and IQ, respectively. Comparing the bi-directional transport 
profile of the three hawthorn flavonoids from individual pure compound 
formulation, cocktail 1, cocktail 2 and plant extract, marginal additive effect of EC, 
HP and IQ on the absorption transport was found among the formulations, and the 
matrix in the hawthorn fruit extract showed no effect on the absorption of the 
hawthorn flavonoids. In addition, transporter competition took place during the 
secretion transport of the mixture forms of hawthorn flavonoids, which resulted in 
reduced amount of the three hawthorn flavonoids being secreted. 
The above findings implied that the extent of the absorption of the studied 
GTC and HF may be similar either in individual pure form or in their mixture orm 
and in extract, whilst MRP2 as well as Phase II metabolism, such as sulfation and 
methylation, may contribute to the in vivo elimination of the studied GTC and HF. 
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Appendix III 
I LC/MS chromatograms of samples taken from the donor 
chamber at the end of the transport experiments of EC. (A) 
Apical loading and apical sampling. (B) Basalateral 
loading and basalateral sampling 
II LC/MS chromatograms of samples taken from the donor 
chamber at the end of the transport experiments of EGC. 
(A) Apical loading and apical sampling. (B) Basalateral 
loading and basalateral sampling 
III LC/MS chromatograms of samples taken from the donor 
chamber at the end of the transport experiments of EGCG. 
(A) Apical loading and apical sampling. (B) Basalateral 
loading and basalateral sampling 
IV LC/MS chromatograms of the samples taken from the 
donor chamber at the end of the transport experiments of 
ECG. (A) Apical loading and apical sampling. (B) 
Basalateral loading and basalateral sampling 
V LC/MS chromatograms of the samples taken from the 
donor chamber at the end of the transport experiment of 
HP. (A) Apical loading and apical sampling. (B) 
Basalateral loading and basalateral sampling 
VI LC/MS chromatograms of the samples taken from the 
donor chamber at the end of the transport experiment of 
IQ. (A) Apical loading and apical sampling. (B) 
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LC/MS chromatograms of samples taken from the donor chamber at the end of the 
transport experiments of EC. (A) Apical loading and apical sampling. (B) 
Basalateral loading and basalateral sampling. EC: epicatechin. EC-sulfate: 
epicatechin sulfate conjugate. Me-EC: methylated epicatechin. Me-EC-sulfate: 
methylated epicatechin sulfate conjugate. 
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LC/MS chromatograms of samples taken from the donor chamber at the end of the 
transport experiments of EGC. (A) Apical loading and apical sampling. (B) 
Basalateral loading and basalateral sampling. EGC: epigallocatechin. EGC-sulfate: 
epigallocatechin sulfate conjugate. Me-EGC: methylated epigallocatechin. Me-EGC-
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LC/MS chromatograms of samples taken from the donor chamber at the end of the 
transport experiments of EGCG. (A) Apical loading and apical sampling. (B) 
Basalateral loading and basalateral sampling. EGCG: epigallocatechin gallate. EGCG-
sulfate: epigallocatechin gallate sulfate conjugate. Me-EGCG: methylated 
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LC/MS chromatograms of the samples taken from the donor chamber at the end of the 
transport experiments of ECG. (A) Apical loading and apical sampling. (B) Basalateral 
loading and basalateral sampling. ECG: epicatechin gallate. ECG-sulfate: epicatechin 
gallate sulfate conjugate. Me-ECG: methylated epicatechin gallate. Me-ECG-sulfate: 
methylated epicatechin gallate sulfate conjugate. 
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LC/MS chromatograms of the samples taken from the donor chamber at the end of 
the transport experiment of HP. (A) Apical loading and apical sampling. (B) 
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LC/MS chromatograms of the samples taken from the donor chamber at the end 
of the transport experiment of IQ. (A) Apical loading and apical sampling. (B) 
Basalateral loading and basalateral sampling. IQ: isoquercitrin. Me-IQ: 
methylated isoquercitrin. 
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